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Despite medical and technological advances, the survival statistics for patients diagnosed 
with glioblastoma have remained stagnant for more than three decades. The invasiveness and 
high recurrence rate of glioblastoma leave both local and systemic therapies ineffective and the 
median survival at an abysmal 12-15 months post-diagnosis. To combat this deadly disease, 
researchers have employed induced neural stem cells (iNSCs). Derived from a patient’s 
fibroblasts, iNSCs have shown the remarkable ability to home to and kill distant tumor foci when 
engineered with lentiviruses encoding cytotoxic proteins and a stem cell-specific transcription 
factor. Yet, when injected into the brain parenchyma in a saline suspension, iNSCs are cleared in 
less than two weeks, thus limiting therapeutic durability. Previous studies have reported that by 
encapsulating iNSCs in a biomaterial matrix, persistence can be significantly improved. This 
dissertation explores how increasing the persistence of iNSCs in vivo impacts therapeutic 
durability and overall survival. Additionally, the safety and toxicity profile of iNSCs, delivered 
in both a biomaterial matrix and injected intracerebroventricularly, is characterized in a canine 
model. Lastly, a bio-inspired matrix for reducing cost and increasing throughput of cell therapy 
studies is presented.  
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CHAPTER 1: INTRODUCTION 
1.1.  GLIOBLASTOMA  
1.1.1. CLINICAL SIGNIFICANCE  
 Glioblastoma (GBM) is classified by the World Health Organization as a Grade IV tumor 
and can present de novo or as a derivative of a pre-existing tumor.1,2 The median age of GBM 
diagnosis is approximately 64 and varies by sex, as males are nearly twice as likely to be diagnosed 
than females.1,3 GBM is a complex disease with high rates of mortality. Moreover, GBM survival 
statistics have remained static for 30 years, leaving the median patient survival at an abysmal 15 
months post-diagnosis.1,4 
Several factors contribute to the complexity of GBM and subsequent dismal survival 
statistics. First, the blood-brain (BBB) barrier is a major hindrance to the delivery of systemic 
therapeutics. The BBB is composed of several cell types: astrocytes, pericytes, and endothelial 
cells which work together to form tight junctions.5 Tight junctions, along with highly selective 
efflux transporters, work to maintain homeostasis in the brain and place strict limits on the types 
of molecules and proteins that can reach the brain parenchyma.5–7 While the BBB plays an 
important role in protecting the brain, it poses a substantial drug delivery challenge. Larger, more 
hydrophilic drugs delivered systemically are unlikely to be transported across the BBB and reach 
target areas in the brain tissue.5 Second, the invasive and diffusive nature of GBM makes surgical 
intervention arduous. GBM primarily presents as a singular tumor at disease onset, these tumor 
cells are highly migratory, and are known to cross into the contralateral hemisphere.8 Surgical 
resection is most feasible in the initial stages of diagnosis when smaller, infiltrative tumor foci are 
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absent.9 Third, GBM is classified as immunologically cold. The lack of infiltrative immune cells 
significantly reduces the anti-tumor response and poses risk for GBM recurrence.10,11 Moreover, 
immunologically cold tumors like GBM have notoriously low mutational rates, which contributes 
to decreased neo-antigen presentation and decreased efficacy of immune checkpoint inhibitors.12–
14 Fourth, the overall GBM tumor microenvironment adds an additional layer of complexity. 
Histologically, the structure of GBM closely mimics that of glial cells, a major cell population in 
the brain.15 Furthermore, the tumor and surrounding microenvironment contribute to increased and 
disorganized blood vessel formation, regions of necrosis, and abnormal cancer stem cell niches are 
present throughout the tumor.16–18 Together, these components make for a complex tumor 
microenvironment.  
Due to this pathophysiology, treatments for GBM patients have focused on highly 
cytotoxic radiation and chemotherapy. Currently, standard of care follows the Stupp 
protocol-maximal safe tumor resection surgery followed by radiotherapy and concomitant 
temozolomide.9,19,20 While temozolomide is administered orally or intravenously (IV), a more 
direct therapeutic delivery strategy can also be used in patients with GBM.21 
Intracerebroventricular (ICV) reservoirs are often implanted at the time of tumor resection. These 
devices consist of a catheter that is fed through the parenchyma into the lateral ventricle; the 
catheter is connected to a reservoir that sits on top of the skull but below the skin. These devices, 
commonly referred to as Ommaya or Rickham reservoirs, are used to deliver chemotherapeutics 
directly into the cerebrospinal fluid (CSF) whilst avoiding challenges of the BBB.22,23 More 
recently, the FDA approved tumor-treating fields as an adjuvant therapy for GBM patients.24 The 
Optune® device emits tumor-treating fields which are pulses of electromagnetic waves which 
work to slow tumor cell proliferation by targeting rapidly dividing cells.25 Despite these 
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interventions, GBM tumors inevitably recur and continue to invade the brain, resulting in 
decreased life spans and poor quality of life in patients.9  
 
 
Figure 1.1. Magnetic Resonance Imaging of GBM. Scans of a patient (A) post-resection and 
(B) after receiving temozolomide and immunotherapy for 3 months. White arrows indicate 
regions of recurrence. Figure reproduce with permission from Springer and the Journal of Neuro-
Oncology.26 
 
1.1.2. IN VITRO AND IN VIVO MODELS OF GLIOBLASTOMA 
The complexity of GBM makes studying the disease challenging, and this is clearly 
reflected in the models currently available (Table 1.1). To date, there is no ‘best model’ widely 
agreed upon by clinicians and researchers. Instead, scientists are tasked with selecting the model 
that is readily accessible, cost effective, and meets the needs of their study. Often, these criteria 
are met to the detriment of equally important criteria like clinical relevance.  
 
 
Table 1.1. Models of GBM.  
Category Model Origin Considerations References 
Cell Lines 
A172 Human Not classified at tumorigenic by ATCC 27,28 
LN18 Human Produce high levels of fibronectin 27,29,30 
LN229 Human Forms vascularized tumors in vivo 27,31 
U87 Human Does not mimic tumor invasion observed clinically. Fully sequenced genome. 27,32,33 
T98G Human Not classified at tumorigenic by ATCC 33,34 
U251 Human Potentially cross-contaminated with other GBM lines. 35,36 
M059K Human Untreated GBM tumor. Cells grown from culture of excised tumor sample.  37,38 
M059J Human 
Same patient sample as M059K. Tumor sample was enzymatically dissociated 
prior to culture. 
27,38 
GBM8 Human Invasive tumor that mimics clinical observations. 38 
C6 Wistar Rat N-ethyl-nitrosourea-induced glioma 27,32 
F98 Fischer Rat 
N-ethyl-nitrosourea-induced glioma. Invasive tumor that mimics clinical 
observations. 
27,39,40 
9L Fischer Rat 
N-ethyl-nitrosourea-induced glioma. Tumor can be established in Winstar 
rats. 
32,39 
BT4C BD IX Rat 
N-ethyl-nitrosourea-induced glioma. High cellularity and irregular 
vasculature.  
32,39 
RT-2 Fischer Rat Avian sarcoma virus-induced glioma 39 
RG2 Fischer Rat N-ethyl-nitrosourea-induced glioma 27,32,39 
GL261 C57BL/6N Mouse 3-methylcholantrene-induced glioma 32,41,42 
GL26 C57BL/6N Mouse 
3-methylcholantrene-induced glioma. Increased necrosis and vascularity 
compared to GL261. 
41,42 
CT-2A C57BL/6J Mouse Methylcholanthrene-induced glioma 41,43 
P560 VM/Dk Mouse Isolated from a spontaneous tumor 44,45 
In vivo 
Xenograft Varies Immunocompromised animal may be required   
Patient Derived Xenograft Human Must use immunocompromised animal model to avoid rejection 41 
Genetically Modified  Mouse Investigate oncogenic genes of interest, expensive  41,46 
Spontaneous Canine Time to establish tumors and inevitable variability amongst animals 47 
Ex vivo 
Organotypic Tissue Slices Rat Improved modeling over plastic culture dishes, high throughput 35,41,48,49 
Organoids Varies High throughput  37,41 
Synthetic Tissue-mimicking Polymer Cost-effective and high throughput. Lack critical biologic features. 37,50,51 
4 
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1.2. STEM CELL THERAPY FOR THE TREATMENT OF GLIOBLASTOMA 
1.2.1. ALLOGENEIC NEURAL STEM CELL THERAPY 
Neural stem cells (NSCs) are found in the subventricular and subgranular zones of adult 
brain tissue.17,52,53 To isolate NSCs, biopsies from the NSC-rich regions of the brain must first be 
obtained.54 The biopsy is then placed into an enzymatic digestion medium to dissociate the cells 
and create a single cell suspension. Finally, the NSCs are segregated from the pool using 
fluorescence-activated cell sorting. While this process yields a homogeneous NSC population, it 
results in a low yield which then have to be substantially expanded in culture.55,56 Ultimately, this 
process is inefficient and cannot be easily implemented in the clinic. 
  To circumvent the challenges of isolating autologous NSCs, researchers established an 
allogeneic NSC line. This cell line, known as HB1.F3, was generated by sequestering NSCs from 
human fetal brain tissue, immortalizing the cells with a v-myc oncogene, and finally selecting a 
specific clone.57 In vitro studies demonstrated that the HB1.F3 cell line retained nestin and 
vimentin expression, two characteristic stem cell markers, after repeated passaging.58,59 Additional 
in vivo studies demonstrated the ability of these cells to differentiate into astrocytes and neurons 
once engrafted into brain tissue, thus verifying their pluripotency.58,60 However, what is most 
unique about NSCs is their innate ability to migrate to tumors.61 Although the exact molecular 
mechanisms that drive tumoritropic NSC migration have yet to be elucidated, there is some 
evidence to suggest that cytokines released by the tumor, such as vascular endothelial growth 
(VEGF) and stromal cell-derived factor 1 (SDF-1), play a role.61 
Researchers have already begun to exploit this migratory behavior to deliver cytotoxic 
payloads to distant tumor foci. However, it is important to note that HB1.F3 cells exhibited 
differences in their ability to reach the tumor foci based on route of administration, IV or 
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intracerebrally (IC), as well as dose. Interestingly, as the number of cells in a single dose increased, 
fewer cells ultimately reached tumor foci. Moreover, cells administered IC were significantly more 
likely to reach the tumor focus (³50%) compared to cells administered IV (<2%). This study also 
noted that there is likely a minimum tumor volume threshold that must be reached in order to 
attract HB1.F3 cells; the authors hypothesized that the lower quantity of cytokines and immune 
cells in the smaller tumor microenvironment is likely the cause of this phenomena.62 Nevertheless, 
understanding the migratory properties of NSCs is just one crucial component of the therapy; the 
cytotoxic capabilities of the cells are the second half of the equation. 
HB1.F3 cells have been engineered to express cytosine deaminase (CD), fragmented 
human metalloproteinase-2, interferon type I-b, or carboxylesterase and has demonstrated efficacy 
against several cancers, including GBM.61 Of these engineering strategies, HB1.F3 cells 
expressing CD (HB1.F3.CD) have shown immense potential in pre-clinical studies. In one study, 
immunocompromised mice were implanted with human GBM cells, and subsequently received 
one of three HB1.F3.CD cell dose levels 0.5 millimeters (mm) caudal-laterally to the tumor 
implantation site. Mice were then administered the prodrug 5-fluorocytosine intraperitoneally (IP) 
twice per day for five days followed by once per day for two days. Significantly smaller tumor 
volumes (15.5 µm3) were observed in the mice that received NSCs and the prodrug compared to 
those that did not receive combination therapy (16.6 µm3). Additionally, blood and tissue samples 
from mice were collected post-mortem for analysis, and importantly, no abnormal findings were 
observed.63  
Due to the success of NSCs in pre-clinical models, several clinical trials have been 
conducted to better understand the safety and efficacy of allogeneic NSCs (NCT02015819, 
NCT03072134, NCT02192359, NCT01172964, NCT02055196).64 Of these trials, NCT01172964 
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explored the safety and toxicity of HB1.F3.CD cells in HLA-matched recurrent human GBM 
patients. Secondary aims of the study sought to explore the immunogenicity as well as the 
migratory abilities of HB1.F3.CD cells. Of the enrolled GBM patients, 15 participated in the study, 
and 12 patients were evaluated for safety and toxicity measures. Patients consisted of both sexes 
and were 22 to 63 years old. Serial blood analyses confirmed the absence of anti-HB1.F3.CD 
antibodies, thus demonstrating safety and reduced risk of therapy clearance. The cells were also 
observed to migrate into the contralateral hemisphere in one patient. Furthermore, while efficacy 
was not an objective of this Phase I study, the investigators noted significance in overall survival 
between patients who received a higher dose (5×107) versus a lower dose (1×107) of cells.65,66 
Overall, this study validated the HB1.F3.CD cell line and laid the groundwork for future NSC 
clinical trials.  
1.2.2. AUTOLOGOUS NEURAL STEM CELL THERAPY 
 While allogeneic NSCs have proven efficacious in vitro and have made headway in human 
clinical trials, autologous NSCs would substantially reduce the risk of an acute immune reaction 
and negate potential long-term toxicity.67 As aforementioned, isolation of autologous NSCs is a 
tedious and laborious process, thus limiting the use of these cells clinically. However, recent 
advances in cellular engineering have allowed researchers to overcome this challenge. 
In a novel approach, fibroblasts, a major cell population in the dermis of the skin, have 
been transformed into neural stem cell-like cells, known as induced neural stem cells (iNSCs), 
using a combination of genetic engineering and transdifferentiation techniques.68,69 Using a normal 
newborn foreskin fibroblast cell line (NHF1), researchers transduced the cells to express SOX2, 
reverse tetracycline-controlled transactivator (rtTA), tumor necrosis factor-related apoptosis 
inducing ligand (TRAIL), and thymidine kinase (TK).26,68,69 SOX2, a transcription factor, is a 
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defining marker of NSCs; it plays a vital role in regulating NSC proliferation, differentiation, and 
migration.70,71 To temporally control the expression of SOX2, an rtTA promoter was used. Lastly, 
the anti-cancer proteins TRAIL and/or TK were constitutively expressed by the iNSCs. TRAIL 
binds to death receptors 4 and 5, which are over expressed on some glioma cells, and activates 
caspase-mediated apoptosis.72,73 On the other hand, TK functions as part of a prodrug system with 
valganciclovir (VGCV). Following administration, VGCV is hydrolyzed and converted to 
ganciclovir (GCV). GCV is then converted to GCV monophosphate intracellularly. Then, GCV 
monophosphate is converted to GCV triphosphate via TK. Finally, GCV triphosphate inhibits 
DNA polymerase, subsequently inducing cellular apoptosis; this process not only kills the iNSC 
but also adjacent tumor cells via the bystander effect. Of note, all transductions were performed 
using replication-incompetent recombinant lentiviruses.74Also, while previous cell differentiation 
strategies have taken cells through the pluripotent stage, converting fibroblasts into iNSCs uses 
transdifferentiation.75 By surpassing the pluripotent phase, the risk of teratoma formation is 
significantly reduced.76,77 As a whole, the rational design of iNSCs provides several advantages 
over other cell types. 
 
Figure 1.2. Autologous iNSC Production Process. 
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Furthermore, iNSCs exhibit robust anti-tumor properties. In vitro, iNSCs exhibit 
directional migration towards tumor cells whereas precursor fibroblasts and transduced fibroblasts 
migrate in a Brownian manner.69 Co-culture assays have also demonstrated the efficacy TRAIL, 
TK, and combination therapy. Here, iNSCs are able to significantly reduce GBM tumor burden as 
early as 48 hrs after plating, and continued decline in tumor viability is observed through day 
seven.68,69 The drug concentration, which is governed by the ratio of iNSCs to tumor cells, also 
plays an important role in time to response. As the ratio increases, the faster the tumor cells are 
eradicated. For example, when iNSCs and GBM cells are cultured in a ratio of 0.5:1, a 0.4-fold 
change in tumor viability is observed in three days; however, when cultured at a 4:1 ratio, the 
GBM cells are nearly completed killed in three days.68 Importantly, these anti-tumor properties 
translate to a potent in vivo response as well. Using xenograft models of human GBM, iNSCs have 
been shown to migrate to the contralateral hemisphere containing a GBM tumor by day 21. 
Notably, mice treated with therapeutic iNSCs survived on average 34 days longer than mice 
receiving non-therapeutic iNSCs.68 
In addition to assessing the migration and therapeutic potential of iNSCs, extensive genetic 
characterization has also been performed. Using ribonucleic acid sequencing (RNAseq), 
expression changes in genes involved in migration, differentiation, immune response, as well as 
others have been studied to compare fibroblasts and endogenous NSCs to iNSCs. Interestingly, 
iNSCs are phenotypic intermediates of fibroblasts and endogenous NSCs, with some gene 
expression levels more similar to those of fibroblasts (e.g. CXCR4, FLT1) and others mirroring 
those of endogenous iNSCs (e.g. HIF1a). Moreover, iNSCs were determined to have high 
expression of NESTIN and SOX2, two NSC markers, and importantly, when forced into 
differentiation, expressed low levels of NANOG and OCT-4, two pluripotency markers.69 While 
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these experiments provided a first look at the genes involved in generating and maintaining an 
iNSC phenotype using NHF1s, subsequent studies have utilized primary human fibroblasts. 
By studying the transdifferentiation of primary human fibroblasts, several key observations 
were made. First and foremost, inter-patient variability was observed in isolated fibroblasts prior 
to and following transdifferentiation. This variability included differences in proliferation rate, 
gene expression, and TRAIL output. When these patient-derived iNSCs were implanted into 
athymic nude mice bearing human xenograft GBM tumors, variations in therapeutic durability and 
survival were also observed. However, extensive RNAseq also identified possible quality control 
markers to identify iNSCs that are more likely to be stronger therapeutic candidates. These include 
proliferation genes (NAMPT and IL1), markers of transduction efficiency (TRAIL and SOX2), and 
migration genes (SEMA3B, PIK3CD, and WWC1).78  
As a whole, autologous iNSCs have shown immense potential as a GBM therapy. These 
studies provided groundbreaking evidence to further propel iNSCs to the clinic. However, what 
remains to be shown is the safety of autologous iNSCs in an immune-competent, large animal 
model and the optimal delivery method.  
1.3. DELIVERY OF NEURAL STEM CELL THERAPIES 
To date, studies investigating scaffold systems have primarily reported on their 
regenerative medicine or tissue engineering capabilities – cartilage, bone, skin, and cardiac tissues 
being the most frequently reported.79–83 The matrices are designed from a plethora of natural and 
synthetic materials with the goal of releasing a drug, growth factor, protein, and/or other agent to 
promote healing.84–87 Researchers have pushed this framework even further and created 
cellularized scaffolds using a variety of cell types, ranging from fibroblasts to stem cells.88 In these 
studies, the cells are intended to integrate into the host tissue while the scaffold simultaneously 
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integrates or degrades.89–92 Moreover, a handful of cellular and acellular scaffold products have 
been approved by the FDA, including, but not limited to, MACI®93, GINTUIT™94, TransCyte™93, 
and Osteoplug™93. Other promising cellularized scaffolds products are currently in clinical trials 
(NCT04188262, NCT03258658, NCT04339764, NCT03463239).95–98 While extensive research 
has been conducted to determine the ideal properties of scaffolds for tissue engineering and 
regenerative medicine, significantly less work has been published on the delivery of more 
specialized cells, like iNSCs, which need unobstructed pathways for migration in order to achieve 
their full therapeutic potential. 
Given the success of iNSCs in early in vivo models, there is reason to believe that 
increasing the persistence of iNSCs would result in increased TRAIL AUC and subsequently 
improve survival outcomes. By encapsulating iNSCs in a biocompatible matrix, it is believed that 
the cells would be sheltered from the acute immune response in the post-surgical resection 
cavity.99,100 While confined within the matrix, iNSCs could continuously secrete cytotoxic proteins 
to attack tumor cells in the immediate vicinity. Then, three to five days after resection, the iNSCs 
could migrate to tumor foci to produce a more durable, anti-tumor response. All the while, the 
material used to deliver the iNSCs could be engineered to further support the cells and reduce 
tumor burden. 
A handful of studies have investigated this hypothesis. Early experiments employed 
electrospun poly-L-lactic (PLA), Gelfoam®, HySTEM™, TISSEEL®, and acetylated dextran 
(Ace-DEX) scaffolds for the delivery of therapeutic stem cells.69,101–104 When the stem cells are 
injected into the brain parenchyma in a saline suspension, nearly all are cleared 10 days post-
implantation; however, stem cells seeded in PLA, Gelfoam®, HySTEM™, TISSEEL®, and Ace-
DEX scaffolds persisted out to 7, 19, 28+,  28, and 120 days, respectively.69,101–104 To explore how 
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increased stem cell persistence correlated to survival outcomes, mice were implanted with GBM 
tumors. The tumors were then resected, leaving residual cells, to mimic clinical procedures. As 
hypothesized, the mice receiving encapsulated therapeutic cells survived, on average, 14, 15, and 
21 days longer when treated with therapeutic stem cells on HySTEM™, Gelfoam®, and 
TISSEEL® scaffolds, respectively, compared to mice that received scaffolds containing non-
therapeutic cells.69,102,103 While these increases may seem trivial, they could correlate to significant 
survival outcomes improvements in human patients down the road, as newly developed therapies, 
like Optune®, are revered for their ability to increase median overall survival by 4.7 months.105 
Despite the substantial evidence to support the benefit of delivering iNSCs via a delivery matrix, 
the optimal material remains unknown.  
1.4. SCOPE AND AIMS 
GBM remains a terminal disease despite extensive research. Although allogeneic NSCs 
have been investigating extensively preclinically and have entered human patient trials, autologous 
iNSCs have yet to reach these milestones. To further propel autologous iNSCs to human clinical 
trials, this work investigated delivery strategies to optimize iNSC therapy and develop novel 
models to study GBM through the following aims: 
1.4.1. AIM 1: CHARACTERIZE FLOSEAL AS A SCAFFOLD DELIVERY SYSTEM TO 
INCREASE PERSISTENCE OF iNSCs 
In Aim 1, the use of FLOSEAL®, an FDA-approved hemostatic agent, is investigated for 
its utility in increasing the persistence of iNSCs in the tumor resection cavity, and how this impacts 
treatment efficacy. FLOSEAL®’s impact on iNSC gene expression profile is also explored. 
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1.4.2. AIM 2: DETERMINE THE SAFETY, TOXICITY, AND PERSISTENCE OF 
AUTOLOGOUS iNSCs IN A CANINE MODEL 
In Aim 2, the safety profile of iNSCs is explored in an immune-competent canine model. 
Two, clinically relevant administration routes are used, intracerebroventricular infusion and 
FLOSEAL® scaffold implantation into the surgical resection cavity, as well as two dose levels. 
1.4.3. AIM 3: DEVELOP A HIGH THROUGHPUT, COST-EFFECTIVE MODEL TO 
STUDY GBM AND EVALUATE STEM CELL THERAPIES 
In Aim 3, bio-inspired matrices are developed with special considerations made for scale-
up and optical imaging. Tumor growth, iNSC migration, and efficacy studies are used to evaluate 
the model as an alternative to animal studies.   
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CHAPTER 2: IMPACT OF A GELATIN-FIBRIN COMPOSITE SCAFFOLD ON 
INDUCED NEURAL STEM CELL PHENOTYPE, PERSISTENCE, AND EFFICACY 
 
2.1.  INTRODUCTION 
 
Glioblastoma (GBM) is an aggressive, stage IV brain cancer and is the most common 
malignant brain tumor in adults.106,107 Current standard of care includes tumor resection, radiation 
therapy, chemotherapy, and alternating electric field therapy.108,109 However, complete tumor 
resection is often unachievable, as GBM is characterized by highly migratory cells that disperse 
far from the primary tumor mass, often into the contralateral hemisphere.10,108 The aggressive, 
infiltrative nature of GBM results in a high mortality rate and a median patient survival of just 15 
months.106  
To combat the migratory nature of GBM, neural stem cells (NSCs) have been investigated 
as drug delivery vehicles due to their innate tumor-tropism. Several pre-clinical studies have 
investigated the persistence, migration, and efficacy of immortalized NSCs bearing a range of 
therapeutic agents in mice.63,110,111 Moreover, immortalized, allogeneic NSC therapy has entered 
human clinical trials for the treatment of GBM (NCT02015819, NCT03072134, NCT01172964, 
NCT02055196, and NCT02192359).112–116 While NSC therapy shows promise, harvesting a 
sufficient quantity of autologous NSCs is challenging, and immortalized, allogeneic cells pose an 
immunogenic risk and have potential for unrestrained proliferation.117,118 We have improved upon 
NSC therapy by developing a rapid, single-transcription factor reprogramming that allows for the 
direct conversion of fibroblasts to NSCs, known as induced neural stem cells or iNSCs. Here, 
fibroblasts are isolated from patient skin and stably engineered with lentiviral constructs encoding 
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for the neural stem cell transcription factor SOX2 and the cytotoxic protein TNFα-related 
apoptosis-inducing ligand (TRAIL). Transduced fibroblasts are then cultured in 
transdifferentiation media to produce therapeutic, tumor-homing iNSCs.69  
While iNSCs are efficacious, persistence in the tumor resection cavity remains a limiting 
factor. When iNSCs are administered to the resection cavity in saline, more than 50% of iNSCs 
are cleared by day 10, and nearly all iNSCs are cleared by day 25 post-implantation.69  To address 
this, previous studies have demonstrated that seeding mesenchymal stem cells on TISSEEL®, a 
fibrin product, and poly(l-lactic acid) significantly improves cell persistence compared to cells 
injected in saline.102,119 Additionally, increased persistence of iNSCs has been observed when 
seeded on Gelfoam®, a gelatin matrix, compared to injection in saline.120 However, the optimal 
characteristics of an iNSC delivery matrix and the relationship between efficacy and increased 
persistence remain unknown. 
Herein, we investigated the use of the FDA-approved, hemostatic agent, FLOSEAL®, a 
gelatin and thrombin mixture, as a delivery matrix and its impact on iNSC persistence and efficacy. 
When subjected to an area with active bleeding, the thrombin component  of FLOSEAL® 
polymerizes with circulating fibrinogen to form fibrin.121,122 We postulated that this rapid 
polymerization would instantly encapsulate iNSCs, and the gelatin granules would swell to create 
a physical barrier, thus providing ample protection from the post-surgical immune response in the 
resection cavity. As FLOSEAL® degrades, the iNSCs would be expected to migrate out of the 
scaffold after the post-surgical immune response has subsided. We theorized that the 6- to 8-week 
resorption timeframe of FLOSEAL® would drastically improve iNSC persistence. In this study, 
we demonstrate that a FLOSEAL®-based transplant significantly improves iNSC persistence 
compared to Gelfoam®, TISSEEL®, and saline injection. The marked increase in persistence lead 
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to improved survival outcomes compared to control-treated animals using two unique GBM 
xenograft models, but extensions over therapeutic cells delivered without a scaffold were modest. 
These results indicate that persistence alone is inadequate as a predictive marker for therapeutic 
efficacy, and further research is needed to develop the optimal iNSC delivery matrix.  
 
2.2.  RESULTS 
2.2.1. ENCAPSULATING CELLS IN FLOSEAL®  
Figure 2.1A depicts the scaffold fabrication process. First, acellular FLOSEAL® scaffolds 
were observed via SEM. The gelatin particles in the FLOSEAL® kit were found to be 
heterogeneous in shape and size; on average, particles were determined to be 250 µm at their 
largest dimension (Fig. 2.1Bi). When combined with thrombin and polymerized with fibrinogen, 
the gelatin particles become wrapped in a fibrin web (Figure 2.1Bii-iii). Similar to the gelatin 
particles, iNSCs were also found to be encased in the fibrin web, and this cell-fibrin network 
encases the gelatin particles (Fig. 2.1Ci-iii). 
2.2.2. SEEDING EFFICIENCY 
After understanding the interaction between cells and FLOSEAL®, seeding efficiency, 
defined as the number of cells calculated to be in the scaffold divided by the theoretical cell count, 
was determined. FLOSEAL® scaffolds were determined to have a 43.43% ± 17.40% seeding 
efficiency on average. The total concentration of DNA per sample was 10.6 ng/µL ± 3.5 ng/µL 
(Fig. 2.1D). Each batch of FLOSEAL® produces six scaffolds contained in a single syringe. To 
ensure consistency between samples, the seeding variability between scaffolds was also analyzed. 
The DNA concentration was found to be 12±7, 9±3, 9±2, 10±3, 12±5, and 10±1 ng/µL for 
scaffolds plated first through sixth, respectively, using linear regression. The total number of cells 
was found to be 4.99´105±3.20´105, 4.46´105±2.11´105, 3.68´105±1.23´105, 
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3.83´105±1.48´105, 4.89´105±2.25´105, and 4.21´105±0.30´105 for scaffolds plated first 
through sixth, respectively. Importantly, no statistical significance was observed between any 
comparison by one-way ANOVA with Šidák correction (Fig. 2.1E). 
 
Figure 2.1. FLOSEAL® Material Characterization. A) Schematic depicting FLOSEAL® 
scaffold fabrication. B) SEM images of i) dry gelatin particulate (Scale bar, 500 µm), ii) 
FLOSEAL® scaffold (Scale bar, 200 µm), and iii) fibrin clot structure (Scale bar, 1 µm). C) 
SEM images of i) gelatin, fibrin, and iNSCs (Scale bar, 200 µm), ii) multiple iNSCs entrapped in 
fibrin (Scale bar, 10 µm), iii) high magnification view of a single iNSC trapped in fibrin (Scale 
Bar, 5 µm). D) Seeding efficiency of fibroblasts in FLOSEAL quantified via DNA 
concentration. Black points represent standard curve (n=3 per cell density). Red point represents 
average cell count and DNA concentration of FLOSEAL® samples (n=18). E) Impact of plating 
order on the number of cells in each scaffold; all comparisons not significant. Data presented as 
mean ± standard deviation. 
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2.2.3. IMPACT OF FLOSEAL® ON iNSC GENE EXPRESSION  
Previous studies have shown that a material’s physiochemical properties can influence 
gene expression, particularly as it relates to markers of differentiation, proliferation, and 
migration.123–126 To understand FLOSEAL®’s transcriptomic impact, therapeutic iNSCs were 
encapsulated in FLOSEAL® and cultured up to two weeks in the matrix using transwell inserts, 
which prevents dissolution of the scaffold in liquid media, to study how the material influenced 
iNSC gene expression (Fig. 2.2A). Gene expression of iNSCs in scaffolds was compared to both 
non-transdifferentiated fibroblasts (Fig. 2.4A-F) and to day 0 iNSCs (Fig. 2.2B-G). ‘Day 0 iNSCs’ 
denotes fibroblasts that have been transduced and transdifferentiated to become iNSCs but not 
placed into a scaffold. Neural stem cell (NSC), differentiation, proliferation, pluripotency, 
migration, therapy, and anti-apoptosis markers were monitored. The differentiation markers, 
namely GFAP, TUBB3, and VMAC, were found to remain fairly constant in their expression levels 
over time, but downregulated compared to the day 0 iNSCs (Fig. 2.2B). Of the NSC markers, 
NESTIN was the only one found to be upregulated (Fig. 2.2C). All pluripotency markers were 
downregulated; however, NANOG was virtually unchanged at the day 7 and 14 timepoints (Fig. 
2.2D). Interestingly, Ki67 and IL-1R, two proliferation markers, were also downregulated (Fig. 
2.2E). Of note, TRAIL and HSPA5, an anti-apoptosis marker, were downregulated (Fig. 2.2F). 
Lastly, we observed wide variability in the expression of migration markers (Fig, 2.2G). SOX2, 
P2RX7, STC1, VCAM-1, FLT-1, and CXCR4 were the most profound upregulations observed. 
To further confirm our findings, we opted to repeat this experiment using three unique batches of 
iNSCs for the day 14 timepoint. In sharp contrast to the findings presented in Fig. 2.2B, GFAP 
was upregulated while TUBB3 and VMAC remained downregulated (Fig. 2.3A). Similar to the first 
gene expression experiment, NESTIN was the only NSC marker to be upregulated, and similar 
trends were observed for NANOG (Fig. 2.3B-C). The proliferation, anti-apoptosis, and therapy 
 19 
markers remained downregulated as well (Fig. 2.3D-E). As for the migration genes, similar trends 
were observed wherein SOX2, STC1, VCAM-1, FLT-1, and CXCR4 were upregulated; however, 
P2RX7 was slightly downregulated in this experiment (Fig. 2.3F). 
 
Figure 2.2. Impact of FLOSEAL® on iNSC Phenotype Over Time. A) qRT-PCR 
experimental design. Gene expression of iNSCs in FLOSEAL® relative to day 0 iNSCs for B) 
differentiation, C) NSC, D) pluripotency, E) proliferation, F) other, and G) migration markers (5 




Figure 2.3. Impact of FLOSEAL® on Day 14 iNSC Gene Expression. Gene expression of 
iNSCs in FLOSEAL® relative to day 0 iNSCs for A) differentiation, B) NSC, C) pluripotency, 





Figure 2.4. Impact of FLOSEAL® on iNSC Phenotype Over Time. A) qRT-PCR 
experimental design. Gene expression of iNSCs in FLOSEAL® relative to day NHF1-hTERT-
SOX2-rtTA-GFP-TRAIL cells for B) differentiation, C) NSC, D) pluripotency, E) proliferation, 
F) other, and G) migration markers (5 scaffolds pooled per time point). 
 
 
2.2.3. IN VIVO iNSC PERSISTENCE 
Next, we sought to compare the persistence of non-therapeutic iNSCs using four different 
implantation techniques: direct injection or encapsulation in FLOSEAL®, TISSEEL®, or 
Gelfoam®. Using bioluminescence imaging (BLI), we observed significant differences in Fluc-
tagged iNSC persistence. iNSCs encapsulated in FLOSEAL® persisted significantly longer than 
iNSCs implanted via direct injection, TISSEEL®, or Gelfoam®. In FLOSEAL®, iNSCs appear 
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to proliferate 21-fold by day 23 post-implantation and show strong BLI signal 95 days post-
implantation. In contrast, iNSCs encapsulated in Gelfoam® and TISSEEL® show near complete 
clearance on or before day 20 and little proliferation is observed (Fig. 2.5A-B). iNSCs delivered 
by direct injection in 1X PBS showed near background signal by day 20, also indicating significant 
clearance. Mice implanted with iNSCs encapsulated in FLOSEAL® were euthanized on day 95, 
and brains were harvested for analysis. Significantly, iNSCs remained clustered in the mock 
resection cavity at this time (Fig. 2.5C).  
2.2.4. IN VIVO iNSC EFFICACY 
After observing significantly improved iNSC persistence with the aid of FLOSEAL®, we 
sought to determine if increased persistence correlated to enhanced therapeutic durability and 
improved survival in mice. We first tested therapeutic durability using the GBM line GBM8. This 
tumor line was selected for its ability to mimic the invasive nature of tumors seen in the clinic. 
Three days after implantation, tumors were resected to reflect clinical procedures and treatments 
were administered into the resection cavity. Tumor size was monitored over time via BLI (Fig. 
2.6A). Mice treated with iNSCs encapsulated in FLOSEAL® initially showed steady tumor 
growth; however, by day 25, some mice began to show decreased tumor growth (Fig. 2.6B, E). 
The direct injection and TISSEEL® groups showed an initial decrease in tumor volume over the 
first 5-10 days; however, this was followed by exponential tumor volume increase in the 
proceeding days (Fig. 2.6C-D). Mice administered non-therapeutic iNSCs displayed rapid tumor 
growth and significantly shorter lifespans compared to all other groups (Fig. 2.6F-G). In contrast, 
mice treated with therapeutic iNSCs survived significantly longer compared to mice treated with 
non-therapeutic iNSCs. The FLOSEAL® low TRAIL (P=0.030), FLOSEAL® high TRAIL 
(P=0.010), and TISSEEL® TRAIL (P=0.022) groups all survived significantly longer compared 
to the FLOSEAL® control group. Despite a trend, a significant difference was not observed in 
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survival between the mice treated with a direct injection of therapeutic iNSCs and the FLOSEAL® 
high TRAIL (P=0.704) or FLOSEAL® low TRAIL groups. (P=0.4595).  
 
Figure 2.5. In vivo Persistence of Cells Encapsulated in FLOSEAL®. A) Fold change in BLI 
signal of non-therapeutic iNSCs over time (n=5 per group) (* indicates P<0.05; **** indicates 
P<0.0001). B) Representative BLI images. C) Fluorescent images of non-therapeutic iNSCs in 







Figure 2.6. In vivo Efficacy of iNSCs Encapsulated in FLOSEAL® Against GBM8 Tumor. 
A) Schematic of surgical procedure and timeline. B) Fold change in GBM8 tumor radiance of 
mice treated with low dose of TRAIL iNSCs encapsulated in FLOSEAL® (n=4), C) direct 
injection of TRAIL iNSCs (n=4), D) TRAIL iNSCs encapsulated in fibrin (n=3), E) high dose of 
TRAIL iNSCs encapsulated in FLOSEAL® (n=4), F) direct injection of control, non-therapeutic 
iNSCs (n=3), and G) control, non-therapeutic iNSCs encapsulated in FLOSEAL® (n=3). Each 
line represents one mouse. H) Kaplan-Meier survival curve of mice implanted with GBM8 






We next tested a second GBM tumor model using the U87 cell line to mimic the primary 
non-migratory tumor mass seen clinically. Seven days after tumor implantation, the tumors were 
resected, and iNSC therapies were administered into the resection cavity (Fig. 2.7A). Mice were 
treated with a direct injection of therapeutic iNSCs in suspension, therapeutic iNSCs encapsulated 
in FLOSEAL®, or control (non-therapeutic) iNSCs encapsulated in FLOSEAL®. Fig. 7B depicts 
the fluorescence-guided tumor resection and implant of the scaffold. Mice treated with a direct 
injection of therapeutic cells exhibited exponential tumor growth following treatment; however, 
one mouse in this group displayed an initial decrease in tumor volume followed by an increase in 
tumor volume (Fig. 2.7D). Mice administered therapeutic iNSCs in FLOSEAL® showed different 
responses within the group. While 70% of mice showed progressive tumor growth within the first 
25 days and ultimately succumbed to tumor burden, 30% of mice displayed slower tumor growth 
and survived beyond 100 days (Fig. 2.7 C, F). As anticipated, mice administered non-therapeutic 
iNSCs encapsulated in FLOSEAL® displayed no tumor suppression (Fig. 2.7E). Despite 
differences in the tumor progression, no significant differences in survival were observed between 
any group comparison.  
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Figure 2.7. In vivo Efficacy of iNSCs Encapsulated in FLOSEAL® Against U87 Tumor. A) 
Schematic of surgical procedure and timeline. B) In vivo surgical images of craniotomy, tumor 
resection, and FLOSEAL® scaffold implantation. C) Fold change in U87 tumor radiance of mice 
treated with TRAIL iNSCs encapsulated in FLOSEAL® (n=10), D) direct injection of TRAIL 
iNSCs (n=5), and E) control, nontherapeutic iNSCs encapsulated in FLOSEAL® (n=5). F) 
Kaplan-Meier survival curve of mice implanted with U87 tumors (ns indicates not significant). 
 
2.3.  DISCUSSION 
Previous work by our group has demonstrated the benefit of delivery matrices to increase 
NSC persistence in the tumor resection cavity.69,102,119,127 While Gelfoam®, TISEEL®, and 
HySTEM™ each statistically improved NSC persistence compared to direct inject controls, iNSCs 
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still failed to persist beyond 28 days.69,102,119,127 In tumors such as GBM where recurrence is 
inevitable, there is a strong need to have the iNSCs persist long enough to migrate vast distances 
across the brain while still constantly producing their therapeutic payload. To achieve this goal, 
we sought to combine the best features of previous materials, specifically taking into account 
biocompatibility, cell binding sites, ease of fabrication, and handleability. Based on these criteria, 
we selected FLOSEAL® as our candidate matrix.  
As an FDA-approved hemostatic product, FLOSEAL®’s intrinsic features make it a 
desirable scaffold material. The two principal components of FLOSEAL®, gelatin and thrombin, 
are biocompatible – gelatin as denatured collagen, and thrombin as a critical component of the 
coagulation cascade.128,129 With gelatin and thrombin as the principal ingredients, FLOSEAL® is 
completely resorbed in patients within 8 weeks and encapsulated NSCs are unlikely to be 
obstructed by fibrotic encapsulation.120,130 For this study, we scaled back the gelatin and thrombin 
components from the FLOSEAL® kit produce smaller scaffold volumes while keeping the ratio 
of the components the same as that used clinically. With this formulation, we observed rapid 
encapsulation of iNSCs in FLOSEAL®. While the gelatin component of FLOSEAL® is rich in 
RGD sequences, which promotes cell adhesion,131 the rapid reaction of thrombin with fibrinogen 
completely wrapped the iNSCs in a fibrin web with insufficient time to adhere to gelatin particles.  
Furthermore, we observed consistent iNSC density across scaffolds. Because the total 
volume of gelatin and thrombin (86 mg and 500 uL, respectively) presented here produces enough 
material to make six scaffolds, we were initially concerned the gelatin particles would be 
compressed during ejection from the syringe, such that the thrombin and cell solution would be 
ejected first, therefore producing scaffolds that were initially more liquid and had a higher cell 
density than those ejected last. Although the first three scaffolds plated were more liquid in nature, 
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no statistical differences were observed in the cell densities, thus ensuring consistent dosing 
between scaffolds. 
Given the volume of literature on the impact of material properties on stem cell 
proliferation, differentiation, and migration, we sought to understand the impact of FLOSEAL® 
on iNSC gene expression. In accordance with previous studies, downregulation of NANOG and 
upregulation NESTIN and SOX2 were observed compared to fibroblasts.69 Downregulation of 
GFAP, TUBB3, and VMAC suggest that FLOSEAL® is not inducing differentiation to glial cells 
or neurons and the iNSCs have transitioned away from a fibroblast phenotype. Surprisingly, TRAIL 
was found to be downregulated at all time points after seeding in FLOSEAL®. However, iNSCs 
were engineered to secrete TRAIL under a constitutive promoter; therefore, additional 
investigation is needed to elucidate these changes. Interestingly, KI67 and IL-1R were found to be 
downregulated. Moreover, downregulation of the anti-apoptosis gene HSPA5 was also observed. 
Despite these findings, we observed a noticeable increase in iNSC signal in our persistence study, 
indicating that additional signaling factors and interaction in vivo contribute to the iNSC 
proliferation. Undeniably, there are limitations to this experimental design. The synthetic transwell 
culture system lacks many components of the in vivo environment that the iNSCs would be 
exposed to, specifically, cytokines, chemokines, immune cells, and tumor cells.132,133 Therefore, 
due to insufficient external stimuli, it is unsurprising that a number of the migration genes probed 
were downregulated. However, the substantial upregulation of SOX2, P2RX7, STC1, VCAM-1, 
FLT1, and CXCR4 suggests that these genes may serve as quality control markers in iNSC therapy 
optimization and scale-up. Notably, studies have demonstrated that post-transcriptional, 
translational, and degradation processes may play an equally important role in protein expression, 
and findings elucidated from mRNA should be interpreted with caution.134 Future studies will 
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explore changes in iNSC gene expression when encapsulated in FLOSEAL® in immune-
competent mice to understand the impact of the resection cavity microenvironment.  
Despite our initial hypothesis that the principal role of gelatin particles would be for iNSC 
adhesion, gelatin appears to have played a separate role in iNSC persistence. One of the key 
features of FLOSEAL® as a hemostatic matrix is its ability to expand as a means of compressing 
and sealing off sources of active bleeding. Based on our remarkable persistence data, we believe 
the gelatin particles acted as a physical barrier, protecting the iNSCs from immune clearance. 
While cells persist in Gelfoam® significantly longer compared to previously tested scaffold 
materials,103 we theorize that the lack of persistence of iNSCs in Gelfoam® in the present study is 
due to poor cell attachment and insufficient penetrance into deeper pores. TISSEEL® also severely 
underperformed in comparison to FLOSEAL®. Importantly, the BLI signal was confirmed via 
fluorescence in post-mortem brain tissue sections. Given the lack of tumor, and its associated 
chemokines to promote iNSC migration, it is not surprising to see the iNSCs clustered in the 
resection cavity after euthanasia on day 95.  
Lastly, we investigated if increased iNSC persistence obtained with FLOSEAL® resulted in 
enhanced therapeutic durability and improved survival outcomes. For these studies, we selected 
two distinct GBM tumor models, GBM8 and U87. Although both tumors proliferate rapidly in 
vivo, neither alone fully mimics what is observed clinically; the U87 cell line produces a dense 
tumor sphere while the GBM8 cell line results in a diffuse tumor that invades both hemispheres. 
It is also important to note that GBM8 cells are more sensitive to TRAIL therapy than U87 
cells.135,136 These attributes explain, at least in part, the differences observed in therapeutic 
durability and mouse survival observed in the GBM-8- and U87-bearing mice. Therapeutic iNSCs 
injected in suspension into the resection cavity provide immediate tumor suppression, but they 
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lack the persistence to provide a durable response. On the other hand, therapeutic iNSCs 
encapsulated in FLOSEAL® do not provide immediate tumor suppression, but the FLOSEAL® 
matrix appears to offer a prolonged therapeutic effect beyond 25 days in select cases. 
FLOSEAL®’s lack of initial burst release likely explains its inability to significantly reduce tumor 
volume initially. For all in vivo studies, as noted in the materials and methods section, cell densities 
in FLOSEAL® scaffolds were theoretical calculations made by obtaining a desired cell 
concentration and assuming equal division amongst the number of scaffolds made. However, the 
seeding efficiency data shows that only a 43% seeding efficiency is achieved on average. 
Therefore, the persistence and efficacy studies were conducted using less than desired cell doses, 
but despite this, promising trends were observed in therapeutic durability and survival. Based on 
these results, there is a clear need for a delivery matrix that allows for an initial burst release of 
iNSCs to combat tumor cells in the immediate vicinity of the resection cavity and sustained release 
of iNSCs to support therapeutic durability.  Future studies will explore how a combinatory burst 
release and sustained release of iNSCs impacts therapeutic durability as well as the impact of the 
immune system on iNSC persistence and treatment efficacy.   
2.4. CONCLUSION 
In this study, we show the impact FLOSEAL® has on iNSC gene expression, persistence, 
and efficacy. While encapsulating iNSCs in FLOSEAL® produced the longest persistence to date, 
only some mice showed a corresponding increase in survival. Moreover, culturing iNSCs in 
FLOSEAL® most notably impacted proliferation, anti-apoptosis, and migration gene expression. 
This data serves as the framework for future scaffold optimization studies as iNSCs advance 
towards human clinical trials.  
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2.5. MATERIALS & METHODS 
2.5.1. CELL LINES 
U87 tumor cells were obtained from the American Type Culture Collection. U87 cells were 
cultured in Dulbecco’s Modified Eagle Medium (Gibco) containing 10% fetal bovine serum and 
1% penicillin/streptomycin (henceforth referred to as standard culture media). GBM8 tumor cells 
were a gift from H. Wakimoto (Massachusetts General Hospital). GBM8 cells were cultured using 
500 mL filtered Neurobasal Medium (Gibco) containing 3 mM/L L-glutamine, 10 mL B27 
supplement (Gemini), 2.5 mL N2 supplement (Gemini), 2 µg/mL heparin, 2.5×104 U/mL 
penicillin, 2.5×104 µg/mL streptomycin, 62.5 µg/mL amphotericin B, 20 ng/mL fibroblast growth 
factor, 20 ng/mL epidermal growth factor. Normal human fibroblasts (NHF1s) were obtained from 
W. Kauffman (University of North Carolina School of Medicine) and were hTERT-immortalized.  
2.5.2. TRANSDUCTION 
Transduction was performed to produce cells expressing optical reporters and therapeutic 
proteins. Fibroblasts were transduced by incubating the cells with 8 µg/mL polybrene and the 
lentiviral cocktail for 24 hrs at 37ºC/5% CO2. The next day, the virus-containing media was 
aspirated and replaced with fresh standard culture media. ‘Non-therapeutic cells’ denotes NHF1 
cells transduced with lentiviruses encoding eGFP-Fluc, SOX2, and rtTA. The eGFP-Fluc plasmid 
construct contained a puromycin-resistance gene to allow for selection of cells. ‘Therapeutic cells’ 
denotes NHF1 cells transduced with eGFP-TRAIL, Fluc, SOX2, and rtTA lentiviruses. GBM8 and 
U87 cells were transduced using lentiviral mCh and Fluc. All lentiviruses were purchased from 
the Duke Viral Vector Core. 
2.5.3. iNSC PRODUCTION 
To manufacture therapeutic and non-therapeutic iNSCs, 2×106 transduced NHF1s were 
plated in a tissue culture-treated T-175 flask using standard culture media. Twenty-four hours later, 
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the media was changed to STEMdiff Neural Induction Medium (Stem Cell Technologies 05835) 
supplemented with 2 µg/mL of doxycycline (henceforth referred to as transdifferentiation media). 
Transdifferentiation media was replaced every other day for five days. On the fifth day, cells were 
harvested using Accutase (STEMCELL Technologies 07922) and passed through a 100 µm filter. 
Harvested iNSCs were immediately used or kept on ice for no more than 4 hrs.  
2.5.4. ENCAPSULATING iNSCs IN SCAFFOLDS 
To encapsulate iNSCs (Baxter ADS201845), the cells were suspended in 500 µL thrombin 
from the FLOSEAL® kit and loaded into one of the Luer lock syringes. The second Luer lock 
syringe was loaded with 86 mg of the gelatin powder. The ratio of thrombin to gelatin powder was 
determined by taking the total volume and weight of the kit components and scaling down to 
numbers appropriate for murine studies. The two syringes were then connected head-to-head and 
passaged back-and-forth twenty times to mix the contents. The contents were left in a single 
syringe and either used immediately or kept on ice, up to 4 hrs. This protocol produces 
approximately 600 µL of cell-scaffold mixture. For in vitro studies, FLOSEAL® scaffolds were 
polymerized with 30 µL of fibrinogen from TISSEEL® kits (Baxter 1501653SP). To encapsulate 
iNSCs in TISSEEL®, 8 µL of fibrinogen was plated into each well of a 6-well plate. Next, iNSCs 
were suspended in 8 µL thrombin and pipetted directly on to the fibrinogen. TISSEEL® scaffolds 
were allowed to polymerize for approximately 15 min at room temperature and then kept on ice, 
up to 4 hrs. Lastly, to seed cells onto Gelfoam®, a 3 mm diameter hole punch was used to create 
uniform scaffold discs. Discs were placed into a 96-well plate and 2.5 µL of the iNSC suspension 
was pipetted directly onto each side of the disc. iNSCs were allowed to adhere for 1 hr at 37°C/5% 
CO2, and were then kept on ice until use, up to 4 hrs. 
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2.5.5. SCANNING ELECTRON MICROSCOPY (SEM) 
A conjectural count of 6×106 therapeutic iNSCs were encapsulated in FLOSEAL® as 
described above. The resulting six scaffolds were polymerized and incubated at 37°C/5% CO2 for 
30 min. Following incubation, scaffolds were submerged in 10% formalin for 30 min. Samples 
were dehydrated using a graded ethanol series of 50%, 75%, 90%, and 100% ethanol. Next, 
samples were dried using a critical point drier (Tousimis Autosamdi-931), placed on aluminum 
stubs, and sputter coated with 6 nm of gold-palladium (Cressington Sputter Coater 108auto). The 
seeded scaffolds were imaged using a FEI Helios 600 Nanolab Dual Beam System microscope 
with a 2kV accelerating voltage.  
2.5.6. IN VITRO SCAFFOLD SEEDING EFFICIENCY 
Non-therapeutic NHF1s were harvested using 0.05% trypsin and counted (ThermoFisher 
Countess II). Next, cells were resuspended to obtain 5×104, 1×105, 5×105, 1×106, 2×106, and 3×106 
cells per tube, and genomic DNA was extracted from each tube per manufacturer’s protocol 
(ThermoFisher K182002). DNA was quantified using a Qubit Fluorometric Quantification system 
(ThermoFisher). Each cell concentration was quantified in triplicate to create a standard curve. To 
quantify seeding efficiency, non-therapeutic iNSCs were encapsulated in FLOSEAL® as 
described above, but not polymerized with fibrinogen. The scaffold mixture was divided into 6 
tubes and DNA was isolated. This experiment was done in triplicate to produce a total of 18 
samples. 
2.5.7. qRT-PCR 
Therapeutic iNSCs were produced as described above and encapsulated in FLOSEAL® at 
a conjectural density of 2×106 cells/scaffold. Seeded scaffolds were plated on 0.4 µm hanging cell 
culture inserts (Millipore MCHT06H48) and polymerized as detailed above. To each well, 2 mL 
transdifferentiation media was added, and samples were incubated at 37°C/5% CO2; 
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transdifferentiation media was replaced every other day. Five or six scaffold samples were 
collected and pooled on days 3, 7, and 14. Immortalized NHF1s transduced with SOX2, rtTA, and 
GFP-TRAIL and therapeutic iNSCs not encapsulated in FLOSEAL® (day 0) served as controls. 
Total RNA was extracted per manufacturer’s protocol (ThermoFisher 12183020), immediately 
converted to cDNA (Invitrogen 11754050), and stored at -80°C until use. qRT-PCR was performed 
using the Applied Biosystems QuantStudio 3 Real-Time PCR System with TaqMan reagents 
(ThermoFisher A44360) and custom primer-probe pairs targeting 30 genes. The thermal protocol 
used is as follows: UNG incubation at 50°C for 2 min and 1 cycle, enzyme activation at 95°C for 
20 sec and 1 cycle, denaturing at 95°C for 1 second and 40 cycles, and annealing/extension at 60°C 
for 20 sec and 40 cycles. Relative fold gene expression was calculated using the ∆∆$! 	method 
using D0 iNSCs as the biologic control and 18s rRNA as the endogenous control. Supplemental 
Table 1 lists genes and corresponding assay IDs. 
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Table 2.1. qRT-PCR Assay Identification Numbers. 

























































Proliferation KI67 IL-1R 
Hs04260396_g1 
Hs00991010_m1 




2.5.8. IN VIVO iNSC PERSISTENCE 
All animal studies were approved by the Animal Care and Use Committee at the University 
of North Carolina at Chapel Hill. 6–8-week-old female, athymic nude mice (Animal Studies Core, 
University of North Carolina-Chapel Hill) were anesthetized using 2.5% inhaled isoflurane and 
placed into a stereotaxic frame. The surgical site was prepared using 70% isopropyl alcohol and 
betadine. An incision was made in the skin on the head of the mouse to expose the skull. Next, 
using a microdrill, a craniotomy was performed on the parietal skull plate. Cold saline and 
 36 
Surgicel® was used to control bleeding. Surgicel® was removed prior to incision closure with 
Vetbond (3M 1469SB). Post-operative pain was managed with 5 mg/kg of subcutaneous 
meloxicam 24 hrs after surgery. Three days following the craniotomy, the mice were anesthetized 
and prepared for cell implantation. The previous wound was reopened, and the exposed dura mater 
was removed using an 18 G needle. Using a vacuum pump, a mock resection cavity was created. 
Next, after bleeding subsided, a conjectural count of 1´106 non-therapeutic iNSCs were implanted, 
either in 4 µL of a 1X PBS suspension or encapsulated in a FLOSEAL®, TISSEEL®, or 
Gelfoam® scaffold. Lastly, the wound was closed with Vetbond, and post-operative pain was 
managed with 5 mg/kg of subcutaneous meloxicam 24 hrs after surgery. iNSC persistence was 
quantified via serial BLI imaging (IVIS Kinetic, Perkin Elmer) using 150 mg/kg D‐luciferin 
(PerkinElmer 122799) in 1X PBS injected intraperitoneally.  
2.5.9. HISTOLOGY 
Mice were anesthetized using 5% inhaled isoflurane. Cardiac perfusion was performed by 
injecting 5 mL 1X PBS followed by 5 mL 10% formalin into the left ventricle of the heart. 
Following cervical dislocation, brains were harvested and immediately fixed by transferring into 
a vial containing 10% formalin. Samples were fixed overnight at 4°C and then transferred to a vial 
containing 30% sucrose in 1X PBS. Samples were kept at 4°C until the tissue sunk. Next, brains 
were prepared for cryosectioning by placing the tissue in a cryomold (Tissue-Tek Cryomold, 
Sakura), covering with optimal cutting temperature compound (OCT), and freezing at -80°C. 
Tissue sections were cut 40 µm thick onto microscope slides. Then, OCT was washed away by 
incubating the sample in 1X PBS at room temperature for 5 min. To visualize cells, the sample 
was stained with DAPI (Invitrogen) and mounted on ProLong™ Gold Antifade Mountant 
(Invitrogen). 
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2.5.10. IN VIVO iNSC EFFICACY 
Mice were anesthetized using 2.5% inhaled isoflurane and placed into a stereotaxic frame. 
The surgical site was prepared using 70% isopropyl alcohol and betadine. An incision was made 
in the skin on the head of the mouse to expose the skull. Next, using a microdrill, a craniotomy 
was performed on the parietal skull plate. Cold saline and Surgicel® were used to control bleeding. 
Surgicel® was removed, and the wound was closed with Vetbond (3M 1469SB). Three days after 
the craniotomy, mice were again anesthetized and prepared for surgery. The wound was reopened, 
and using a stereotaxic auto-injector, 1´105 U87-mCh-Fluc cells or 3´105 GBM8-mCh-Fluc cells 
suspended in 1X PBS were infused into the brain parenchyma at a rate of 1 µL/min, avoiding the 
lateral ventricles. Cells were given 5 min to settle before slowly removing the syringe. The wound 
was closed with Vetbond. Seven days after implanting the U87 tumors and 3 days after implanting 
the GBM8 tumors, mice were anesthetized and prepared for surgery. The wound was reopened, 
and the tumors were resected using fluorescence guidance and a vacuum pump. Once bleeding 
subsided, therapeutic iNSCs were implanted in a 1X PBS suspension or encapsulated in 
FLOSEAL®. For the GBM8 efficacy study where two doses of iNSCs were tested, ‘FLOSEAL® 
high’ TRAIL denotes mice that received 1.5´106 therapeutic iNSCs, and ‘FLOSEAL® low 
TRAIL’ denotes mice that received 6´105 therapeutic iNSCs conjecturally. All other groups 
received 1´106 therapeutic or non-therapeutic iNSCs, again noting conjecturally for the 
‘FLOSEAL® Control iNSC’ group. In the U87 efficacy study, FLOSEAL® TRAIL denotes mice 
that received 1.5´106 therapeutic iNSCs conjecturally, and all remaining groups received 1´106 
therapeutic or non-therapeutic iNSCs again noting conjecturally for the ‘FLOSEAL® Control 
iNSC’ group.  Post-operative pain was managed with 5 mg/kg of subcutaneous meloxicam 24 hrs 
after surgery. iNSC Tumor volume was monitored over time via BLI (AMI HTX, Spectral 
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Instruments Imaging). Animals were euthanized when more than 20% of their original body 
weight was lost or when the animal displayed physical symptoms of pain-based dehydration, 
hunched position, tremors, and cold body temperature. 
2.5.11. STATISTICAL ANALYSIS 
Replicate number is defined by n in figure legends. All data presented as mean ± standard 
deviation unless otherwise stated. Seeding efficiency data analyzed via one-way ANOVA with 
Šidák’s multiple comparisons test. iNSC persistence data analyzed via one-way ANOVA mixed 
effects analysis with Šidák’s multiple comparisons test. Survival curves analyzed via log-rank 
(Mantel-Cox) test. In all graphs, * indicates P<0.05, ** indicates P<0.01, *** indicates P<0.001, 







CHAPTER 3: PERSONALIZED INDUCED NEURAL STEM CELL THERAPY: 
GENERATION, TRANSPLANT, AND SAFETY IN A LARGE ANIMAL MODEL1 
 
3.1.  INTRODUCTION 
The notoriously hard-to-treat brain tumor glioblastoma (GBM) consists of highly 
infiltrative cells. Standard treatment for patients with GBM consists of maximal tumor surgical 
resection followed by chemoradiotherapy. However, obtaining clean tumor margins is difficult, 
and residual tumor cells invade normal brain tissue, creating distant tumor foci.137 Curtailing tumor 
recurrence with systemic therapies has seen limited success as the blood brain barrier (BBB) 
tightly regulates the passage of molecules from systemic circulation to the brain parenchyma, 
which prevents many chemotherapies from reaching infiltrative GBM cells.138 Treatment advances 
for GBM must combat tumor recurrence by targeting the infiltrative cells that remain after standard 
therapy.  
Induced neural stem cells (iNSCs) generated by the direct transdifferentiation of fibroblasts 
from a patient’s own skin have recently shown promise as drug carriers for GBM due to their 
innate tumor tropism and low immunogenicity.69 These tumor-seeking cells are genetically 
engineered to express cytotoxic proteins as they migrate towards invasive cancer cells. Early 
testing of iNSC therapy in pre-clinical models have demonstrated the effectiveness of iNSCs 
generated from human donors against human xenografts of GBM in athymic nude mice.68,69,104 
Although the athymic mouse model recapitulates many aspects of human tumor  
 
1This chapter previously appeared as an article in the journal Bioengineering & Translational Medicine. The original 
citation is as follows: Bomba, H.N., et al. Personalized Induced Neural Stem Cell Therapy: Generation, Transplant, 
and Safety in a Large Animal Model. Bioeng Transl Med. (2020). 
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resection surgery, it is understandably limited in its ability to test iNSC doses on par with what 
would be administered to a human patient as well as its ability to elucidate any potential adaptive 
immune reactions. Additionally, a small animal model cannot accurately mimic the size of the 
surgical cavity or fluid volumes that iNSCs may be delivered into during initial human patient 
testing. A large animal model is needed to bridge the gap between mouse models and a first-in-
human Phase I clinical trial. 
Canine models can be used to bridge this translational gap, as gliomas occur spontaneously 
in canines with phenotypes and genetic mutations similar to humans.47,139 While this study focused 
on testing the safety and toxicity of iNSCs in healthy, non-tumor-bearing canines, this was an 
important consideration when selecting an animal model that would be compatible with future 
efficacy studies. Despite the potential of this large-scale model, the generation of iNSCs from 
canine skin has not yet been reported. Additionally, the exploration of the delivery, dosing, and 
safety of autologous or allogeneic tumor-homing cell therapies has primarily focused on the 
murine model and is extremely limited in large animal models.63,140,141 As such, we sought to 
demonstrate the feasibility of manufacturing, as well as the safety and toxicity of autologous 
therapeutic iNSCs using healthy canine patients. The iNSCs used in this study carry two 
therapeutic agents. The first therapeutic agent is TNFα-related apoptosis inducing ligand (TRAIL), 
a constitutively expressed protein that is continuously secreted into the extracellular space. TRAIL 
diffuses to nearby cells but initiates caspase-mediated apoptosis by engaging death receptors 
upregulated on cancer cells.142 Importantly, TRAIL has been well-tolerated and has shown 
negligible off-target toxicities in normal cells in both pre-clinical and clinical studies.143–146 The 
second constitutively expressed protein is the enzyme thymidine kinase (TK). TK remains inactive 
until administration of its non-therapeutic prodrug substrate valganciclovir (VGCV). VGCV is 
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first hydrolyzed into ganciclovir (GCV) in the liver and intestine, and subsequently, TK expressed 
by iNSCs phosphorylates circulating GCV into cytotoxic ganciclovir triphosphate (GCV-TP). 
Finally, GCV-TP inhibits DNA polymerase, consequently killing both the iNSC and nearby tumor 
cells via the bystander effect.147,148 TK-VGCV therapy exhibits limited toxicity on normal brain 
cells due to their quiescent state.149–151 
Using our early-stage studies in murine models as a guide, we demonstrate the production, 
safety and toxicity of autologous therapeutic iNSCs transdifferentiated from canine skin for the 
first time. Healthy, purpose-bred canines were successfully administered two dose levels of 
autologous iNSCs using two clinically relevant delivery methods: intracerebroventricular (ICV) 
infusion and scaffold encapsulation.152,153 We further demonstrate the safety and minimal toxicity 
signals in the canine model using MRI, blood, urine, cerebrospinal fluid (CSF), neurological 
assessment, and histopathology. These promising results pave the way for future efficacy studies 
in a spontaneous canine glioma model as well as human clinical trials. 
3.2.  RESULTS 
3.2.1. GENERATION OF CANINE iNSCs: ISOLATION, EXPANSION, & 
CONVERSION 
Previously, we have shown the ability to convert mouse and human fibroblasts into tumor-
homing iNSCs.69 Using these studies as a guide, we first explored the feasibility of generating 
personalized canine iNSCs (Fig. 3.1A). First, full thickness (epidermis and dermis) skin biopsies 
were collected from donor canines. Once the animals were anesthetized, a skin biopsy was isolated 
from the base of the neck and placed into a tube containing collection media (Fig. 3.1B-C). To 
isolate the fibroblasts, skin biopsies were manually diced into approximately 6 mm pieces (Fig. 
3.1D) and placed in digestion media containing a low concentration of collagenase, thus enabling 
long dissociation conditions without negative impacts on cell viability.154,155 Following 
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dissociation, the tissue pieces were seeded in culture plates containing growth media, and 
fibroblasts were allowed to grow for 72 hrs. Once fibroblasts had expanded, the cells were 
trypsinized, filtered to removed unwanted solid tissue, and the remaining fibroblasts were allowed 
to proliferate rapidly. As shown in Fig. 3.1E, we observed robust outgrowth of fibroblasts from all 
biopsies. While fibroblasts initially proliferated reproducibly after each passage, cell senescence 
was observed as early as passage 12 for some fibroblast lines (data not shown). This timeline 
dictated the fibroblast transduction and transdifferentiation processes. As we have shown 
previously, we used the SOX2 transcription factor to and transdifferentiation media to convert 
fibroblasts into tumor-homing iNSCs.69 To explore the potential of converting canine fibroblasts 
into canine iNSCs, we transduced the canine cells with lentiviral vectors encoding reverse 
tetracycline-controlled transactivator (rtTA) and SOX2, as well as the therapeutic and optical 
reporters mCherry-thymidine kinase (mCh-TK), and enhanced green fluorescent protein (eGFP) 
fused to TRAIL. Following transduction and five days of transdifferentiation with culture in the 
presence of doxycycline, >85% of cells expressed TRAIL and >95% of cells expressed TK as 
demonstrated by eGFP and mCh fluorescence, respectively (Fig. 3.1F). Additionally, 
immunofluorescence staining showed nearly all cells expressed transgenic SOX2, suggesting 
efficient transduction and conversion to the iNSC phenotype (Fig. 3.1G). In total, three fibroblast 








Figure 3.1. Murine Proof-of-Concept Studies. A) Schematic depicting fibroblast isolation, 
transduction, and transdifferentiation procedures. B) Skin biopsy harvest from cadaver canine. C-
D) Skin samples in digestion media. E) Cultures of primary canine fibroblasts 16 hrs after plating 
and prior to filtering, 30 min after filtering, and 16 hrs after filtering. Scale bar 100 μm. F) 
Fluorescence imaging confirming TRAIL expression in fibroblasts. Scale bar 100 μm. G) 
Immunofluorescence imaging of transdifferentiated fibroblasts to confirm SOX2 expression. 
Scale bar 50 μm. H) Quantification of iNSCTRAIL+/TK- and MDA-MB-231-Br 42 hr coculture 
assay. I) Quantification of iNSCTRAIL-/TK+ and MDA-MB-231-Br 72 hr coculture assay. J) 
Quantification of iNSCTRAIL-/TK- and MDA-MB-231-Br 25 hr coculture assay. All data 
presented as mean ± standard deviation. 
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3.2.2. INVESTIGATING TUMORITROPIC MIGRATION & TUMOR KILLING OF 
CANINE iNSCs 
After confirming transduction and transdifferentiation of canine fibroblasts to iNSCs, in 
vitro functional assays were conducted to test the migratory and tumor-killing capability of the 
new therapeutic cells. The metastatic breast cancer cell line, MDA-MB-231-Br (231-Br), which 
was isolated from brain metastases, was selected as the model tumor for in vitro assays because of 
its ease of growth and sensitivity to TRAIL. Tumor-homing migration is one of the most critical 
aspects of stem cell therapy for cancer. To investigate canine iNSC migration, we used real-time 
motion analysis and co-culture assay systems. Using a two-well migration insert, the directional 
migration of iNSCsTRAIL-/TK- towards 231-Br tumor cells was clearly observed while non-
transdifferentiated fibroblasts moved in a Brownian manner in the 500 µm gap, which similar to 
our previously published data for mouse and human iNSCs (supp. movies 1-3). Next, a co-culture 
assay was used to evaluate the killing capacity of the canine iNSCs lines against 231-Br cells. The 
cytotoxicity of iNSCTRAIL+/TK- and iNSCTRAIL-/TK+ were tested individually. To explore the efficacy 
of TRAIL monotherapy, we found that total tumor luminescence decreased as the ratio of 
iNSCsTRAIL+/TK- to 231-Br cells increased. A 1:20 ratio of iNSCsTRAIL+/TK- to 231-Br cells was 
sufficient to produce a 5-fold reduction in tumor viability compared to the 0:1 tumor-only controls. 
Promisingly, a 100-fold reduction in tumor viability was observed when iNSCs were cultured in a 
1:1 ratio with 231-Br cells compared to 0:1 tumor-only controls following 42 hrs of co-culture 
(Fig. 3.1H). Moreover, time-lapse imaging showed 50% of the 231-Br cells were dead in less than 
10 hrs, and nearly 100% of 231-Br cells are dead in less than 24 hrs (supp. movie 4). Next, 
exploring the efficacy of TK mono-therapy using iNSCTRAIL-/TK+ cells, we found a nearly 2-fold 
reduction in tumor viability at 72 hrs in the 1:20 iNSC:tumor group compared to the 0:1 tumor-
only control group for all samples (Fig. 3.1I). In the absence of TRAIL and VGCV, we showed 
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the iNSCs did not induce apoptosis and allowed the 231-Br cells to expand (Fig. 3.1J). Overall, 
these data suggest that canine iNSCs have the ability to seek out tumor cells and induce tumor 
apoptosis. Importantly, these results also showed similar migratory and killing potencies in all 
three canine iNSC lines, thus demonstrating the reproducibility of this technology. 
3.2.3. DEVELOPING METHODS FOR MRI TRACKING OF CELLS 
Tracking iNSCs in patients is highly beneficial, allowing insights into persistence and 
distribution. Although fluorescent- and bioluminescent-tracking is valuable in pre-clinical models, 
the use of these modalities in human patients is limited by light penetration and other challenges. 
To generate a method for tracking iNSCs that is compatible with canines and eventual human 
patients, we opted to label fibroblasts with superparamagnetic iron oxide nanoparticles 
(ferumoxytol) for MRI. Fibroblasts were used in lieu of iNSCs to expedite this experiment. 
Ferumoxytol is an FDA-approved iron replacement therapy and has recently been explored for its 
use as a cell-labeling agent.156–158 Importantly, ferumoxytol has been shown to have no impact on 
cell viability or stemness, and the iron particles are not readily exocytosed, making it an ideal 
labeling agent for long-term tracking of iNSCs.156,159 To investigate the potential of labeling 
fibroblasts for MRI tracking with this agent, the canine cells were transfected with ferumoxytol 
and assessed for particle uptake in vitro. As shown in Fig. 3.2A, Prussian blue staining of cultured 
fibroblasts showed homogeneous uptake of iron oxide particles in the fibroblasts. After confirming 
labeling in vitro, we next assessed imaging and tracking of the labeled cells in vivo. Unlabeled 
fibroblasts, ferumoxytol-labeled fibroblasts, and free ferumoxytol were injected into the brain 
parenchyma of mice. Changes in volumes were then tracked using MRI over three days (Fig. 
3.2B). Analysis of images showed the cells and free ferumoxytol injection sites are clearly visible 
in all samples on the day of implant. The unlabeled and iron-labeled fibroblasts appear confined 
to a single location in the brain, whereas free ferumoxytol spreads from the injection site. By the 
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third day post-infusion, unlabeled and iron-labeled fibroblasts remain constrained at their initial 
injection site, but the free ferumoxytol particles continue to spread medially, caudally, and invade 
the contralateral hemisphere. To confirm imaging results, mice were sacrificed following MR 
imaging on day three, brains were harvested, and tissue sections were probed for the presence of 
iNSCs (Fig. 3.2C). Strong eGFP fluorescence was observed at the site of injection, and Prussian 
blue staining confirmed the colocalization of iNSCs with iron oxide particles. We believe these 
studies suggest that we have the ability to isolate and transduce primary canine fibroblasts, 
transdifferentiate fibroblasts to iNSCs, kill tumor cells using both TRAIL and TK/VGCV, and 
track iNSCs in mice using MRI. Taken together, these in vitro and murine in vivo studies laid the 
foundation for the canine scale-up model. Building on this knowledge, we designed a canine study 
to evaluate the safety and toxicity of autologous canine iNSCs at low and high doses using two 
delivery mechanisms anticipated to be used clinically. 
3.2.4. STUDY DESIGN TO TEST DELIVERY & DOSING 
In the clinical setting, patient skin biopsies will be collected and converted into iNSCs, 
which will then be delivered back into patients following surgical resection as part of clinical 
standard of care for GBM patients. Using our expertise in canine neurosurgery, we created a 
surgical resection cavity and explored the delivery of iNSCs into the brain using two methods: 1) 
intra-cavity seeding within a bio-compatible matrix, and 2) infusion into the CSF through a 
reservoir implanted in the lateral ventricle. Four healthy, male canines were randomized into one 
of two study arms: ICV injection or scaffold implantation. One canine in each cohort was to receive 
1⨉106 autologous iNSCs/kg per dose, and the other canine was to receive 3⨉106 autologous 
iNSCs/kg per dose. Canines in the ICV cohort, referred to from here on as canine patient 01 and 
02 (CP01 and CP02), received a total of three iNSC injections every four weeks, while canines in 
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Figure 3.2. Detection of Fibroblasts via Magnetic Resonance Imaging. A) Prussian blue 
staining of ferumoxytol-labeled fibroblasts. Scale bar 50 μm. Magnified image scale bar, 10 μm. 
B) Comparison of MR images using unlabeled fibroblasts, ferumoxytol -labeled fibroblasts, and 
injection of ferumoxytol suspension over 3 days. C) Histological sections of mouse brain 
injected with ferumoxytol-labeled fibroblasts. Fluorescence (top) depicts fibroblasts, and 
Prussian blue stain (bottom) depicts ferumoxytol particles. Scale bar 200 μm. 
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the scaffold cohort, referred to from here on as canine patient 03 and 04 (CP03 and CP04), received 
a single scaffold implantation (Fig. 3.3A). Animal health and iNSC detection was monitored via 
routine physical and neurological examinations; blood, urine, and CSF screenings; and MRI. At 
specified time points, canines were assessed for toxicity. If no toxicity or adverse safety signals 
were observed, the animal was to continue with the study; however, if a toxicity or safety signal 
was observed, the second canine in the cohort was redirected to the other study arm (Fig. 3.3B-C).  
3.2.5. MANUFACTURING & SCALE-UP OF CANINE iNSCs 
We next worked on expanding the canine iNSCs manufacturing process. Upon delivery, 
canines underwent a physical examination to ensure suitability for the study. CP01, CP02, and 
CP04 weighed 15-20 kg at the time of biopsy. CP03 weighed slightly less at 12 kg. After 
confirming animal health, full-thickness skin biopsies were surgically excised and autologous 
iNSCs were manufactured for each patient. One of the biggest challenges in this study was scaling-
up manufacturing procedures for a canine from a mouse model. As expected, interpatient 
variability was seen in fibroblast proliferation and transduction efficiency. This made it 
challenging to predict the iNSC yield after transduction and transdifferentiation. For CP01, we 
successfully generated the full 1⨉106 iNSCs/kg dose. CP01 received 15⨉106, 14⨉106, and 
15⨉106 iNSCs at each dose, respectively. CP02 did not receive the target dose of 3⨉106 iNSCs/kg 
any of its three doses; CP02 was administered 20⨉106, 17⨉106, and 12⨉106 cells for the first, 
second, and third doses, respectively. The goal of 1⨉106 iNSC/kg was reached for CP03 and the 
canine was implanted with a scaffold containing 12⨉106 iNSCs total. CP04 did not reach the dose 
goal of 3⨉106 iNSCs/kg but was implanted with a scaffold containing 25⨉106 iNSCs total. Further 
optimization of these processes and incorporation of large-scale cell culture platforms (e.g. 
bioreactors) in the future would ameliorate manufacturing scale-up challenges.  
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Figure 3.3. Canine Safety and Toxicity Study Design. A) ICV and scaffold treatment arm 
dosing. B) ICV study arm timeline. C) Scaffold treatment arm timeline. 
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3.2.6. AUTOLOGOUS TRANSPLANT OF CANINE iNSCs INTO THE BRAIN 
Brain surgeries are notoriously complex procedures. We sought to closely mirror the 
surgery and subsequent cell implant in human patients in our canine model. As a first step, we 
used digital navigation to guide surgery. Canines were anesthetized and custom bite plates with 
fiducial markers were re-affixed to the canine’s maxillary dental arcade (Fig. 3.4A). Due to the 
conformation of the canine teeth, it was challenging to fit the bite plates in the canines.  This risked 
the accuracy of the surgical navigation. Next, the stereotaxic frame was placed around the head of 
the animal (Fig. 3.4B) and an incision was made to expose the skull (Fig. 3.4C). Using a high-
speed drill, a craniotomy was performed to expose the cerebrum (fig. 4D). The BrainSight system 
was utilized for neuronavigation using previously obtained MRI scans (Fig. 3.4E-F). Under the 
guidance of this system, we confirmed key anatomic locations and aspiration was used to remove 
brain tissue to create a mock resection cavity (Fig. 3.4G). For canines in the scaffold cohort, the 
iNSCTRAIL+/TK- cells were encapsulated in a FLOSEAL® matrix and seeded into the resection 
cavity (Fig. 3.4H). For the ICV cohort, a separate burr hole was created and an ICV catheter was 
placed into the ipsilateral (right) lateral ventricle, leaving the reservoir within the skull burr hole 
below the temporalis muscle and skin (Fig. 3.4I). iNSCTRAIL+/TK- cells were then injected into the 
reservoir (Fig. 3.4J). Although the lateral ventricle was accessed and CSF obtained in both canines 
in the ICV cohort, the ICV catheter tip was not precisely placed within the ventricle in either canine 
due to bite plate inaccuracies and the small size of canine lateral ventricles. Following 
iNSCTRAIL+/TK- therapy administration, the incisions were closed with sutures and staples (Fig. 
3.4K). Canines in the ICV cohort received two subsequent cell doses, given every four weeks. For 
additional doses, the canines were anesthetized, the skin was sterilized, and ultrasound was used 
to locate the ICV reservoir (Fig. 3.4L-M). The iNSCTRAIL+/TK- cells were administered using a 
syringe and needle through the skin and muscle without the need to re-open the surgical incision  
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Figure 3.4. Canine Intra-operative Procedure. A) Application of bite plate and attached 
fiducial markers onto upper dental arcade. B) Fixation of skull in stereotaxic frame and 
attachment of BrainSight navigation system. C) Exposing the skull. D) Craniotomy. E-F) Using 
the BrainSight system to locate lateral ventricles. G) Resection cavity. H) Injection of 
iNSCTRAIL+/TK- cells suspended in FLOSEAL®. I) Implantation of ICV reservoir. J) Close-up of 
injection of iNSCTRAIL+/TK- cells into ICV reservoir. K) Wound closure. L) Use of ultrasound to 
locate ICV reservoir. M) Sonogram depicting curvature of ICV reservoir.  N) Injection of 
iNSCTRAIL+/TK- cells into ICV reservoir. 
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(Fig. 3.4N). Throughout the surgical procedures, special considerations had to be made to maintain 
sterility while handing off the syringe containing the iNSCTRAIL+/TK- cells. Importantly, no acute 
injection site reactions were observed in any of the canines following iNSCTRAIL+/TK- 
administration. VGCV was administered orally to each canine patient 14 days after receiving an 
iNSC dose for a total of 5 days. 
3.2.7. ASSESSMENT OF COGNITIVE FUNCTION 
All animals underwent neurological examination after recovering from the intracranial 
surgery. Neurological deficits were limited to visual defects in the eye contralateral to the surgical 
site in CP01, CP03, and CP04 and transient postural reaction deficits in the contralateral limbs of 
all canines. These post-operative changes were consistent with the cerebral resection and were not 
considered a safety signal of the iNSCs.  
3.2.8. TRACKING PERSISTENCE OF AUTOLOGOUS iNSCs 
We anticipated the autologous nature of iNSCs would allow the cells to avoid immune 
rejection, where the longer persistence could offer advantages in efficacy. However, the 
persistence of personalized iNSC carriers in autologous, immune competent models is unknown. 
Similar to the proof-of-concept murine studies, MRI was used to track iNSC persistence and assess 
ICV reservoir placement. We first focused on analysis of canines in the ICV group. Interestingly, 
MRI images from this group suggested that the ICV catheter tip extended beyond the lateral 
ventricle in the case of CP01 and is positioned slightly dorsomedially to the lateral ventricle in the 
case of CP02. Despite the partially missed placement, analysis of the MRI images (Fig. 3.5A) 
showed a hypointense region that remained present through 84 days with no marked reduction in 
the hypointense signal over time, suggesting iNSCs may persist for several months post-infusion. 
We next turned our focus to iNSCs delivered via intracavity scaffolds. As shown in Fig. 3.5B, the  
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Figure 3.5. Canine MR Imaging. Transverse T2* MRI of canine patients in the A) ICV cohort 
and B) scaffold cohort. Hypodense regions (white arrows) indicate presence of blood and/or 
ferumoxytol. Close up of hypodense region outline by white box. 
B 
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hypointense regions were less evident for CP03 compared to CP04, likely due to the depth of the 
resection cavity and/or iNSC dose. However, a hypointense region was clearly visible for CP04 
within 14 days post-implant that remained stable and detectable through 56 days post-transplant. 
While T2* MRI was used to track the presence of iNSCs, it also denotes the presence of blood as 
it detects the presence of iron in hemoglobin. However, it is expected that blood and its degradation 
products would resorb over time and a reduction in the hypointense signal would be observed.160 
As the hypointense region persisted nearly 60 days post-transplant, and without dramatic changes 
in volume, we believe this suggesting that the hypointense signal is indicative of iNSCs rather than 
hemoglobin. 
3.2.9. ASSESSING THE SAFETY OF PERSONALIZED iNSC THERAPY 
Demonstrating iNSCs are safe is one of the most important parameters to test as iNSCs 
move towards human patients. Although human iNSCs have previously been shown to be safe, 
these studies were limited as they were performed in immune-depleted mice. The autologous 
transplant into fully immune-competent canines offers the potential to more accurately assess 
iNSC safety in a model mirroring personalized human iNSC therapy. To investigate the safety of 
iNSCs, canine health was assessed using complete blood count, blood chemistry, urine, and CSF 
(Fig. 3.6). As anticipated, elevations in white blood cells (WBCs), segmented neutrophils, 
aspartate aminotransferase (AST), and alanine aminotransferase (ALT) were noted immediately 
following surgery. These elevated levels were attributed to the post-surgical immune response and 
muscle manipulation during surgery. Interestingly, all canines experienced cyclic neutropenia 
throughout the study. The observation was first noted in CP01 and CP03 and correlated to MRI 
days. To ensure the effects were not caused by medications and anesthesia (including IV fluid 
therapy), peripheral blood was drawn and analyzed in three ways for CP03 on day 70: (1) prior to 
any medications or handling, (2) during IV catheter placement after premedication with  
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Figure 3.6. Canine Fluid Analysis. Select complete blood count and blood chemistry findings, 
including: A) White blood cell, B) hemoglobin, C) lymphocyte, D) segmented neutrophil, E) 
glucose, F) globulin, G) albumin, H) AST, and I) ALT findings. Dotted lines denote normal 
reference ranges for canines. 
 
hydromorphone and midazolam but before anesthesia with propofol and isoflurane, and (3) after 
receiving all anesthetics and medications and after MRI. All blood draws indicated neutropenia in 
CP03. For CP02 and CP04, blood was drawn after administration of hydromorphone and 
midazolam but prior to propofol, isoflurane, and MRI. There was some evidence of a dilutional 
effects of the fluid therapy on blood cell counts. However, surprisingly neutropenia was observed 
on both MRI and non-MRI days, unlike in CP01 and CP03. There was also some evidence to 
suggest that VGCV can cause neutropenia. However, we cannot rule-out iNSC-induced 
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neutropenia.161 Importantly, urine and CSF findings were unremarkable (data not shown). We also 
assessed all major organs for any signs of abnormal pathology following necropsy (Fig. 3.7). As 
anticipated, there were some notable findings near the ICV reservoir implantation site and the 
scaffold implantation site. These findings included: mild to moderate chronic inflammation, mild 
fibrosis, gliosis, and axon degeneration. Fibrous thickening and chronic inflammation were 
observed in the meninges in the region of the resection cavities of CP01 and CP02.  
 
Figure 3.7. Canine Histology. Hematoxylin and eosin staining contralateral brain, resection 
cavity, testicular tissue at necropsy, and testicular tissue collected pre-surgery. Scale bar, 100 
µm. 
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No abnormalities were identified in the contralateral brain in all canines. However, histologic 
changes in the brain and meninges near the resection cavities in the current study were attributed 
to post-surgical wound healing. Additionally, histology showed acute spinal cord hemorrhage in 
all canines, which was attributed to perimortem CSF collection. Observed bone marrow 
hyperplasia in CP01 was interpreted as a response to the neutropenia detailed above. Spleen, lungs, 
adrenal glands, liver, and lymph nodes were unremarkable in all canines. However, pathology did 
note moderate testicular degeneration and aspermia in CP01 and CP03 that was not anticipated. 
To further investigate this finding, unilateral castrations of canines CP02 and CP04 were 
performed to determine if testicular findings were age-, iNSC-, or drug-related. No other 
unanticipated abnormal pathological findings were observed (Fig. 3.8). To further investigate the 
testicular abnormalities, unilateral castration was performed on CP04’s right testis on the day of 
craniotomy and the left testis was harvested at necropsy. For CP02, unilateral castration of the 
right testis was performed 15 days after craniotomy; the left testis was harvested at necropsy. The 
testis of CP02 harvested at necropsy showed marked tissue degeneration. Aspermia in addition to 
no active spermatogenesis were observed in the testicle harvested at necropsy in CP04. Due to the 
extent of degeneration observed in the testes of CP01 and CP03 at necropsy, age-related causes 
were ruled out. Given the normal histopathology of the pre-surgery testis in CP02, we attributed 
the abnormal pathological findings in the testes to the VGCV. GCV and acyclovir have both shown 
extensive reproductive toxicity in animal models, and the FDA has issued a boxed warning for the 
reproductive toxicity of VGCV.162–164 These findings strongly suggest that the abnormal testicular 
pathology seen in the canines is the result of VGCV and not a direct toxicity of the iNSCs. While 
this cannot be ascertained for certain without additional control canines, we opted to limit our 
study to four animals for humane reasons. 
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Figure 3.8. Canine Histology. Hematoxylin and eosin staining of canine spleen, liver, lung, 
bone marrow, and lumbar spinal cord. Scale bar, 200 µm. 
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3.3.  DISCUSSION 
NSCs are an emerging new platform for cancer treatment. Their ability to home to distant 
tumor foci as well as their ability to carry cytotoxic payloads makes them an attractive therapy for 
GBM. Pre-clinical studies have demonstrated the efficacy of allogeneic human NSCs and human 
iNSCs in murine models.63,68,69,148 Promisingly, allogeneic NSCs have entered human clinical 
trials.165 However, until now, little data has been published on autologous iNSCs using an animal 
model that more closely mimics the human condition. To our knowledge, this is the first study to 
explore the safety, toxicity, and persistence of autologous iNSCs in a large animal model and 
serves as foundational work for future human clinical trials. 
We selected a canine model for several key reasons. First, we required an immune-
competent animal. Previous studies using NSCs have been mostly limited to immuno-
compromised mice, and therefore lack the ability to identify any adverse reactions or potential 
safety signals of iNSCs.63,68,69 Second, it is well established that murine models are not fully 
indicative of human conditions. The canine anatomy more closely mimics the spatial scale of 
humans. Furthermore, unlike murine models, which are often inbred, our canine model allowed us 
to explore interpatient variability. As anticipated, we observed varying proliferation rates and 
transduction efficiencies in our canine patient fibroblast lines, and these results mimic what is 
observed in human patients. Third, we desired an animal model that developed GBM tumors 
similar to that of humans. While xenograft models of GBM in mice, zebrafish, and drosophila have 
been studied, canines spontaneously develop glioma lesions with characteristics similar to those 
of human tumors.166–168 Again, while this study used non-tumor-bearing canines, this was an 
important consideration for future research. Combining all of this information, we felt a canine 
model would be best suited to evaluate the safety of iNSCs and served as the ideal model for 
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forthcoming efficacy studies. 
By employing the canine model, we have demonstrated the ability to reproducibly 
manufacture therapeutic, autologous iNSCs. Using small, full-thickness skin biopsies, we 
produced large pools of fibroblasts that could easily be cryostored for future use or immediately 
transduced and transdifferentiated to become therapeutic iNSCs. Clinically, we envision the 
process of obtaining skin biopsies to be incorporated into patient standard of care. Overall, while 
we successfully established personalized canine iNSCs lines, there is room for improvement in 
cell manufacturing scale-up. One of the most challenging aspects of this study was culturing 
millions of cells for each dose. During the cell collection process, we observed entrapment of cells 
in extracellular matrix nets, and despite trituration and enzymatic digestion, total iNSC yield 
increased only marginally. Future studies will explore the use of bioreactors to increase culture 
efficiency and iNSC yield.  
Moreover, we also explored two delivery mechanisms to implant iNSCs in the brains of 
canines. We first investigated intrathecal delivery using a Rickham® reservoir. ICV reservoirs are 
used in patients with GBM to deliver chemotherapeutics into the lateral ventricle. Here, 
chemotherapy follows the flow of CSF to cover the brain and spinal cord and reaches tumor foci 
via diffusion. While this system is FDA approved and bypasses the blood brain barrier, passive 
diffusion will prevent the chemotherapy from reaching deep tumor foci.169,170 Therefore, we 
believed that combining the ICV reservoir with our migratory iNSCs would overcome several 
challenges of current treatment strategies and provide a pathway for future clinical translation. In 
parallel to ICV reservoirs, we also explored a novel delivery strategy using the FDA approved 
hemostatic matrix FLOSEAL®. FLOSEAL®’s natural components and hydrogel structure made 
it a promising, biocompatible choice for delivering iNSCs. We hypothesized that encapsulating 
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iNSCs in FLOSEAL® would increase cell persistence, and in future studies, would correlate to 
increased survival. Our MRI data suggests that FLOSEAL® aids in iNSC persistence. Histology 
further shows no unanticipated brain lesions, demonstrating FLOSEAL®’s safety. Overall, we 
found utility in both delivery mechanisms and believe either device could be used to dispense large 
iNSC doses into human GBM patients.  
With the canine model, we were also able to establish the safety of iNSCs by conducting 
neurological assessments, screening fluids, and analyzing histology. Postural, gait, and vision 
abnormalities observed in canines mimicked possible adverse reactions during human brain 
surgery. Additionally, iNSCs did not elicit any concerning safety signals, regardless of ICV 
reservoir or FLOSEAL® scaffold delivery, as determined by blood, urine, or CSF. The transient 
neutropenia and reproductive toxicity findings were unanticipated, but these could due to 
administration of the prodrug VGCV rather than the iNSCs.  
3.4. CONCLUSION 
In conclusion, this research demonstrates the feasibility of manufacturing autologous 
iNSCs as well as their limited toxicity profile. We further show two clinically translatable methods 
for delivery. Together, this data supports the need for additional large animal efficacy studies and 
paves the way for future human clinical trials. 
3.5. MATERIALS & METHODS 
3.5.1. TISSUE HARVEST & DIGESTION 
Skin samples were harvested from canines at North Carolina State University; animals 
were euthanized for reasons unrelated to this study. Immediately following euthanasia, hair was 
removed using an electric trimmer. The harvest site was sterilized with betadine followed by 70% 
ethanol, repeated three times. Full thickness skin samples were acquired using a 6 mm diameter 
biopsy punch. Biopsies were placed in a 15 mL conical tube containing 10 mL 1X PBS and 2X 
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antibiotic-antimycotic and transported on ice to the University of North Carolina at Chapel Hill. 
Skin biopsies were individually transferred into new 15 mL conical tubes each containing 1 mL 
digestion media (DMEM containing 20% FBS, 1% penicillin-streptomycin, 0.25% Collagenase 
type I, and 0.05% DNase) and incubated at 37°C/5% CO2 overnight. The next day, the conical 
tubes were vortexed for 20 seconds to disrupt the skin and disintegrate the dermis. Approximately 
7 mL fresh DMEM containing 20% FBS and 1% penicillin-streptomycin was added to the 15 mL 
tube, and the contents were mixed and transferred to a 10 cm Petri dish. The dishes were returned 
to the 37°C/5% CO2 incubator and left undisturbed for 72 hrs.155 
3.5.2. FIBROBLAST EXPANSION & CELL CULTURE 
After 72 hrs, media was exchanged for fresh DMEM (henceforth containing 10% FBS and 
1% penicillin-streptomycin). Fibroblasts were cultured in this state until the plate reached >70% 
confluency. Cells were then expanded and subcultured by lifting in 0.05% trypsin-EDTA for 5 
mins, adding DMEM to neutralize trypsin, centrifuging at 1000 rpm for 5 min, aspirating 
supernatant, re-suspending in fresh DMEM, and re-plating in new 15-cm Petri dishes. Cell 
strainers (100 µm) were used to separate single cells from residual tissue pieces. 
3.5.3. LENTIVIRAL TRANSDUCTION & TRANSDIFFERENTIATION 
Fibroblasts were co-transduced with lentiviral reverse tetracycline-controlled 
transactivator (rtTA), SOX2, TK-mCh, and TRAIL-eGFP (Iowa University and Duke University 
Viral Vector Cores). To transduce fibroblasts, cells were incubated with virus and 1 g/mL 
polybrene overnight at 37°C/5% CO2. The following day, the mediate containing virus was 
aspirated and replaced with fresh DMEM. Cells were monitored for fluorescent signal. Next, to 
transdifferentiate cells to iNSCs, transduced fibroblasts were plated at a density of 2x106 cells per 
15 cm Petri dish in DMEM and incubated overnight at 37°C/5% CO2. The following day, DMEM 
was replaced with STEMdiff Neural Induction Medium (STEMCELL Technologies 05835) 
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containing 2 µg/mL doxycycline (NIM+doxy). NIM+doxy media was replaced every other day 
for a total of 5 days.  
3.5.4. IMMUNOHISTOCHEMISTRY 
To confirm lentiviral transduction of mCh-TK and eGFP-TRAIL vectors into fibroblasts, 
fluorescence microscopy was conducted prior to transdifferentiation of the cell lines. Cells were 
monitored daily until maximum fluorescence intensity was observed. Percent fluorescence 
expression was quantified in ImageJ. To determine extent of transdifferentiation, cells were fixed 
in 10% formalin for 15 min and washed three times in 1X PBS. Next, cells were incubated in 
blocking buffer (0.5% bovine serum albumin and 0.25% Triton X-100 in 1X PBS) for 30 minutes 
at room temperature. Primary rabbit anti-SOX2 (Abcam ab97959) antibody was diluted 1:200 in 
blocking buffer and incubated for 1 hr at room temperature on a shaker. After three 1X PBS rinses, 
goat anti-rabbit Alexa Fluor 488 secondary antibodies (Invitrogen A27034) were diluted 1:600 in 
blocking buffer and incubated for 1 hr at room temperature on a shaker, protected from light. After 
three PBS rinses, Hoechst was added to the samples and incubated for 5 minutes on a shaker, 
protected from light. Samples were then washed in 1X PBS and imaged. Transduction was deemed 
successful if >70% of the cells expressed mCh and eGFP, and cells were considered 
transdifferentiated if >70% of the cells were positive for SOX2.  
3.5.5. IRON OXIDE LABELING 
On the fifth day of transdifferentiation, iNSCs were labeled with ferumoxytol (AMAG 
Pharmaceuticals) for MRI imaging. Briefly, 0.0125 mg/mL Lipofectamine 2000 (Invitrogen 
11668027) and 0.15 mg/mL ferumoxytol were added to OptiMEM (Gibco), and incubated at room 
temperature for 1 hr. Next, NIM+doxy media was aspirated from each dish and replaced with 8 
mL of the ferumoxytol media. iNSCs were incubated for 4 hrs with the ferumoxytol media at 
37°C/5% CO2. At the completion of 4 hrs, media was aspirated, cells were rinsed with 1X PBS, 
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and NIM not containing doxy was added back into the dish. Cells were incubated overnight at 
37°C/5% CO2. 
3.5.6. CELL COLLECTION 
Following transduction and transdifferentiation, iNSCs were harvested for dosing. First, 
NIM was aspirated from the dishes. Next, cells were incubated with 4 mL of Accutase 
(STEMCELL Technologies 07922) at room temperature for 5 min. Dishes were then washed with 
4 mL of 1X PBS and passed through 100 µm Falcon Cell Strainers (Fisher Scientific 08-771-19). 
Cells were then pelleted at 1000 rpm for 5 min. The supernatant was then aspirated, and the cells 
were resuspended in 1X PBS for counting. To count the cells, a 1:1 dilution was made in Trypan 
Blue (Invitrogen T10282), and the cells were quantified by a Countess II Automated Cell Counter 
(Invitrogen). For canine studies, cells were transported on ice to North Carolina State University, 
and at the time of craniotomy, cells that were to be injected ICV were resuspended in 600 µL of 
artificial CSF (TOCRIS 3525). 
3.5.7. IN VITRO CELL MIGRATION 
Two-well inserts (Ibidi 80209) were placed in dry tissue-culture treated 6-well plates. 
8⨉104 MDA-MB-231Br-mCh-Fluc cells (gift from Dr. Toshiyuki Yoneda, University of Texas 
Health Science Center at San Antonio) were seeded in DMEM in one well of the insert and 4x104 
canine iNSCs or control canine fibroblasts were seeded in DMEM in the second well of the insert. 
Cells were incubated overnight at 37°C/5% CO2. The following day, DMEM was aspirated and 
the two-well insert was removed. The cells were then incubated in NIM and serial fluorescence 
imaging (EVOS FL Auto) was performed over 66 hrs to assess migration. 
3.5.8. SCAFFOLD PREPARATION & CELL SEEDING 
iNSCs were prepared as described above. FLOSEAL® kits (Baxter 1503350) and 
components were prepared according to manufacturer’s instructions. Briefly, lyophilized thrombin 
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was reconstituted in 200 mM CaCl2. The prepared thrombin solution was used to resuspend the 
iNSC cell pellet, and the cell/thrombin solution was loaded into the provided female Luer 
connector syringe. Next, the Gelatin Matrix was loaded into the Luer Lock syringe; the syringe 
was sterilized via UV light. Following sterilization, the syringes were connected head-to-head and 
passaged 20 times to thoroughly mix. The iNSC-containing FLOSEAL® matrix was kept on ice 
until use. 
3.5.9. MURINE IN VIVO SURGICAL PROCEDURES 
All murine procedures were approved by the Animal Care and Use Committee at the 
University of North Carolina at Chapel Hill. 6-8-week-old female nude athymic nude mice 
(Animal Studies Core, University of North Carolina-Chapel Hill) were anesthetized using 2.5% 
inhaled isoflurane and stabilized in the prone position in a stereotaxic frame. The surgical site was 
sterilized using 70% isopropyl alcohol and betadine. Next, a midline incision was made on the 
mouse’s head to expose the skull, and the underlying fascia was removed using a cotton swab. 
Then a burr hole was created with a microdrill. Using a Hamilton syringe, 1x106 unlabeled canine 
fibroblasts or ferumoxytol-labeled fibroblasts were injected into the brain parenchyma at 1 
µL/min. 9 µL of ferumoxytol was used as a positive control. Following injection, the syringe was 
left untouched for 5 min to prevent reflux. The syringe was then removed slowly, and the incision 
was closed with Vetbond tissue adhesive (3M 1469SB). Post-operative pain was managed with 5 
mg/kg meloxicam. 
3.5.10. MURINE MAGNETIC RESONANCE IMAGING 
T2 rapid acquisition with relaxation enhancement (RARE) MR images were taken using a 
Bruker 9.4 T BioSpec scanner. A 72 mm quad-volume coil (Bruker Biospin) was used for 
radiofrequency transmission. Images were acquired using a repetition time of 10000 ms, echo time 
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of 8 ms, 15 averages, 51.05 Hz bandwidth, 0.75 mm slices, and 0.1x0.1x0.75 mm resolution. Mice 
were anesthetized with 3% inhaled isoflurane. 
3.5.11. MURINE ORGAN HARVEST & TISSUE PROCESSING 
Mice were anesthetized with 5% isoflurane. Cardiac perfusion was done using 5 mL 1X 
PBS followed by 5 mL 10% formalin into the left ventricle of the heart. Extracted brains were 
incubated in 10% formalin overnight. The next day, brains were incubated in 30% sucrose in 1X 
PBS at 4°C until the tissue sank. Brains were then mounted using OCT compound, cut into 40 µm 
sections, and analyzed as floating sections. To detect the presence of ferumoxytol-labeled iNSCs, 
tissues were stained with Prussian blue following manufacturer’s instructions (Eng Scientific Inc. 
3160).  
3.5.12. CANINES 
Four 1-2-year-old, purpose-bred male beagles were obtained from a United States 
Department of Agriculture Class A vendor (Oak Hill Genetics). The weights of CP01-CP04 were 
14.5, 17.0, 9.9, and 14.8 kg, respectively, prior to surgery. Canines were co-housed in groups of 
2, fed a commercial diet twice daily, and provided water ad libitum. Physical and neurological 
examinations, a complete blood count, serum biochemistry and urinalysis were performed at 
admission to confirm clinically healthy status. All canine procedures were approved by the 
Institutional Animal Care and Use Committee at North Carolina State University. 
3.5.13. CANINE ANESTHETIC & SAMPLING PROCEDURES 
Canines were anesthetized for MRI, CSF collection and surgical procedures.  Canines were 
premedicated with hydromorphone (0.1 mg/kg intramuscularly [IM]) and midazolam (0.25 mg/kg 
IM) and anesthesia was induced with propofol (4 mg/kg intravenously [IV] to effect) and 
maintained with isoflurane in oxygen (1-3% to effect).  Cerebrospinal fluid samples were collected 
from the cerebellomedullary cistern. Urine samples were collected by urethral catheterization. 
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Blood, urine, and CSF samples were collected periodically from the canines before and after iNSC 
implantation. 
3.5.14. CANINE iNSC PRODUCTION 
The skin of the dorsal cervical region was prepared as described above and 1 x 3 cm full 
thickness, rectangular skin biopsies were obtained and placed into transport media on ice.  iNSCs 
were manufactured as described above.  For post-operative analgesia, canines were given 
carprofen (4.4 mg/kg SQ followed by 4.4mg/kg PO q 24 hrs for 3 days). 
3.5.15. CANINE MAGNETIC RESONANCE IMAGING 
Magnetic resonance imaging (MRI) was conducted using 3 different systems as the study 
overlapped with the decommissioning of an older MRI unit (Siemens 1.5 Tesla Symphony), 
installation of an upgraded system (Siemens 3.0 Tesla Skyra), and use of a “bridge” unit (Siemens 
1.5 Tesla Symphony equipped with older software).  Sequences obtained included T1-weighted 
fast spin echo (FSE), T2-weighted FSE, T1- and T2-weighted fluid attenuated inversion recovery 
(FLAIR), gradient echo (T2*) and susceptibility-weighted imaging (SWI).  T1-weighted images 
were also obtained after administration of Gadoversetamide (0.1 mmol/kg, Optimark, 
Mallinckrodt Inc., St. Louis, MO).  For the initial MRI studies, a T1-weighted, 3D volumetric 
sequence was also obtained (MP-RAGE) for use with a veterinary neuronavigation system 
(BrainSight, Rogue Research, Montreal, Canada).  Bite plates affixed with MRI-compatible 
fiducial markers were also utilized in this initial MRI study as a prelude to neuronavigation and 
were created using Hydroplastic impression material (Tak Systems, Wareham, MA). 
3.5.16. CANINE CRANIECTOMY & iNSC IMPLANTATION 
In preparation for craniectomy, canines were anesthetized as described above except that a 
continuous infusion of propofol (200 ug/kg/min) was utilized to decrease isoflurane requirements.  
Canines were mechanically ventilated, the head was shaved and surgically prepared and placed in 
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a head frame for neuronavigation (BrainSight, Rogue Research).  The bite plate made prior to the 
first MRI was replaced and used to register the canine for neuronavigation. The iNSC were 
delivered in a FLOSEAL® scaffold in two canines and through an intraventricular catheter in the 
other two canines.  To simulate a resection cavity remaining after tumor removal, a craniectomy 
was created using a high-speed drill followed by durotomy.  A 2x2 cm region of cerebral cortex 
and underlying white matter was removed, centered on the marginal gyrus near the junction of the 
parietal and occipital lobes.  In CP03 and CP04, the iNSC-FLOSEAL® scaffold was injected into 
the resection cavity; in the canines with intraventricular catheters, the resection cavity was left 
unfilled. The dura was then manually apposed and covered with an artificial dural product 
(DuraGen Plus, Integra LifeSciences, Plainsboro, NJ).  Neither the dura nor the craniectomy defect 
were primarily closed.  In CP01 and CP02, an intraventricular catheter was placed into the right 
lateral ventricle after creation of a 6-mm burr hole.  The catheter was attached to a Rickham® 
reservoir that was seated into the burr hole to create a ventriculostomy system (Codman Holter 
Rickham® reservoir, Integra LifeSciences).  The temporalis muscle, subcutaneous tissues, and 
skin were closed using suture and the skin was closed using staples.  A fentanyl patch (50-75 µg/hr) 
was placed immediately following surgery, and hydromorphone (0.1 mg/kg IV q 6 hours) was 
administered until the patch took effect approximately 12 hours after placement. For CP01 and 
CP02, ultrasound navigation was used to inject the second and third iNSC doses into the 
Rickham® reservoir. 
3.5.17. CANINE CASTRATION 
In order to further investigate potential reproductive toxicity, CP02 and CP04 underwent 
unilateral castration for histopathological analysis and sperm evaluation. These procedures were 
performed using standard techniques and the contralateral testis was similarly evaluated at the time 
of autopsy. 
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3.5.18. CANINE POST-OP PROCEDURES & MONITORING 
Following intracranial surgery, all canines underwent a neurological exam to assess gait, 
motor function, postural reactions, segmental spinal reflexes, and cranial nerve function. Blood 
samples were collected from the ICV cohort at baseline prior to surgery, every other post-operative 
day through day 7, and then once per week through week 12. The scaffold cohort had blood drawn 
at baseline, every other post-operative day through day 7, and then once per week through week 
8. Urine and CSF were collected from the ICV cohort at baseline and every 2 weeks through day 
84. The scaffold cohort had urine and CSF collected at baseline and every 2 weeks through day 
56. All animals were routinely monitored for adverse events, pain, and signs of infection. The 
fentanyl patch, which was applied immediately following during surgery, was removed after 5 
days. VGCV was administered 2 weeks following scaffold implantation and 2 weeks after each 
ICV dose at 450 mg PO qd 5 days. 
3.5.19. CANINE EUTHANASIA & NECROPSY 
At the study endpoint, all canines were euthanized via an intentional sodium pentobarbital 
overdose at 85 mg/kg. Necropsy was performed immediately after euthanasia. Tissue samples 
were fixed in 10% formalin overnight in preparation for histological analysis. 
3.5.20. CANINE HISTOLOGY 
Hematoxylin and eosin staining was performed on 5 µm sections of formalin-fixed, 
paraffin-embedded tissue samples. Histopathologic analysis was performed by board-certified 
veterinary pathologists (L.B.B., D.A.T.).  
3.5.21. STATISTICAL ANALYSIS 





CHAPTER 4: DEVELOPING BIO-INSPIRED 3D MODELS OF BRAIN CANCER TO 
EVALUATE TUMOR-HOMING INDUCED NEURAL STEM CELL THERAPY1 
 
4.1. INTRODUCTION 
Primary malignant brain tumors are responsible for the most years of life lost of any 
cancer.171 Of these, glioblastoma (GBM) is the most common and aggressive. Surgery, followed 
by chemoradiotherapy remains the standard of care, but unfortunately results in a median survival 
of under 2 years and a 5-year survival rate of <5%.172 A major reason GBM remains difficult to 
treat is the highly invasive nature of the disease, where migratory tumor cells invade healthy brain 
tissue, making recurrence and associated patient mortality nearly inevitable.104,173,174 Additionally, 
there is a lack of noninvasive methods of local delivery. Systemic delivery, on the other hand, is 
hindered by both the blood/ brain barrier and vascular dysfunction in the tumor, which is 
exacerbated by the fact that many current drugs have short half-lives and therefore do not 
accumulate to therapeutic concentrations in the brain.104,175,176 Moreover, brain metastases 
outnumber primary brain tumors significantly in frequency and result in an even lower median 
survival: <1 year.174 New treatments are desperately needed to improve outcomes in all types of 
brain cancers.  
In efforts to develop therapies that are more effective against brain cancer, neural stem 
cells (NSCs) have been increasingly explored as drug delivery vehicles. Their inherent tropism to  
 
 
1This chapter previously appeared as an article in the journal Tissue Engineering Part A. The original citation is as 
follows: Carey-Ewend, A. et al. Developing Bioinspired Three-Dimensional Models of Brain Cancer to Valuate 
Tumor-Homing Neural Stem Cell Therapy. Tissue Eng. Part A. (2020). Reproduced with permission from Mary Ann 
Liebert, Inc and Tissue Engineering Part A.  
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tumoricidal agents, to which they confer increased persistence along with active targeting.176–179 
Based on the strength of promising preclinical data in mice, NSC therapy recently entered human 
clinical trials. Despite the promising advancements, numerous questions around NSC therapy 
remain due to gaps in relevant models that bridge the size and scale of NSC brain therapy from 
murine models to human patients.  
Tumor-selective homing is one of the most critical and unique aspects of NSC therapy, yet 
little is known about tumor homing at distances unachievable in size-constrained mouse models. 
Studies using large animal models are costly to perform in vivo and cannot be recapitulated at 
scale in commonly used, less-expensive rodent cancer models. As such, in vitro cell migration-
based assays remain the mainstay of NSC homing. These include: (1) measurement of cell 
movement across a scratch or gap, (2) detection of cells having moved through a membrane from 
one chamber to another, or (3) measurement of cell movement in microfluidic devices capable of 
three-dimensional (3D) culture.180–183 Each strategy is limited in terms of the number of cells that 
can be investigated, and these techniques do not recapitulate migration at the longer distances 
necessary in a human brain.184  
Moreover, two-dimensional (2D) culture especially fails to incorporate the physical and 
chemical cues that regulate NSC migration in vivo and restricts cell–cell interactions.182 In fact, 
cells grown in 2D cultures differ significantly in phenotype and genotype from cells grown in vivo 
or in 3D bioinspired hydrogels.185 To overcome these limitations we developed a custom, scalable 
3D hydrogel system referred to as bioinspired brain matrix (BBM). The model is composed of an 
agarose base and has poly-l-lactic acid (PLA) 6100 fibers embedded throughout to simulate neural 
pathways for cell migration.186 The PLA fibers are distributed homogenously throughout the BBM 
to create a consistent density of fibers. The use of agarose as opposed to other hydrogels, such as 
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gelatin, was influenced by material autofluorescence and availability. Our studies suggest that this 
new BBM offers a cost-effective, clinically relevant platform for investigation of the spatial and 
temporal kinetics as well as the efficacy of tumor-homing NSCs used to treat brain cancers. We 
believe our results suggest BBM is a useful surrogate for investigating key questions that are 
beyond the reach of traditional animal or cell cultures as new cell therapies are advanced toward 
human patients.  
4.2. RESULTS 
4.2.1. BBM FABRICATION AND BIOREACTOR DESIGN  
To develop cost-effective models that will allow investigation of NSC therapy on a larger 
scale, two versions of the 3D hydrogel model were produced. The first was a life-sized BBM that 
measured ~1.5´103 cm3 in volume, and the second was a mini-BBM that was ~7.5cm3, which is 
comparable to small rodent in vivo models. Figure 1A depicts schematically the development and 
use of BBMs to study cell growth and migration. Briefly, PLA was sterilized through UV light for 
30min in a tissue culture hood and incubated overnight in 3D cell culture medium (DMEM, 1% 
FBS, 1% antibiotic–antimycotic). Next, 0.6% agarose (w/v) was dissolved in 1:1 PBS:3D cell 
culture medium and poured over PLA in the plastic mold. Gelation occurred as the agarose cooled 
at room temperature. Importantly, the resulting BBM was optically transparent to enable 
noninvasive tracking of cell populations within the matrix.  
The mini-BBM (Fig. 4.1B) could be cultured in 6-well polystyrene plates (Fig. 4.1C). 
However, it was necessary to design a bioreactor in which to culture the human-size BBM (Fig. 
4.1D). To this end, a 6-L round polycarbonate container was used as a central housing. An acrylic 
lid was laser cut to the container’s dimensions. The lid was rationally designed with filter inserts 
to allow for proper gas exchange while remaining sterile. The bioreactor was designed to be 
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compatible with serial noninvasive optical imaging, thus the walls and lid comprised material that 
was optically transparent, whereas the base and fittings were designed with black material to 
minimize the reflection of light during imaging. A custom impeller was 3D printed to circulate 
nutrients throughout the bioreactor without creating a circular flow pattern that could shear parts 
of the BBM contained within, a common issue with standard stir bar-based bioreactors.187  
 
Figure 4.1. BBM and Bioreactor Design. A) Schematic of workflow for BBM fabrication and 
use in cell growth assay. (B) Representative image of mini-BBM with schematic representation 
of example set up for tumor-homing assay. (C) Small BBMs can be cultured in polystyrene 
tissue culture plates. (D) Representative image of large BBM (with added pink dye for contrast). 
(E) Custom bioreactor for life-size BBM. BBM, bioinspired brain matrix. 
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4.2.2. CELL–BBM INTERACTIONS  
To next investigate the interaction between the PLA fibers and agarose, as well as cell 
distribution and attachment to the matrix, we utilized scanning electron microscopy (SEM). The 
SEM images showed that while the PLA fibers were primarily dispersed evenly throughout the 
matrix, more condensed groups of fibers were present in certain locations (Fig. 4.2A, B). The 
average PLA fiber diameter was determined to be 15.83-1.99 mm through ImageJ analysis (n = 
10) (Fig. 4.2C). With increasing magnification of the BBM agar component, the continuous 
morphology of the material was interspersed with cracks, which were likely an artifact of the 
critical point drying procedure (Fig. 4.2D). Following injection of tumor cells, cell clustering and 
attachment to the agar matrix was observed, directly adjacent to the PLA fibers (Fig. 4.2E, F).  
 
Figure 4.2. BBM Characterization. Interaction between PLA and agar is visualized in (A–C). 
Cells attached to agarose adjacent to PLA is pictured at low magnification in (E) and high 
magnification of white square in (F). Scale bars are as follows: (A) 1 mm, (B) 500 mm, (C) 100 
mm, (D) 40 mm, (E) 300 mm, and (F) 50 mm. (G) Percent light transmittance of BBMs with and 
without PLA fibers; n = 3 for samples with PLA fibers; n = 6 for samples without PLA fibers;  
*p < 0.05. PLA, poly-l-lactic acid. 
 
4.2.3. IMPLANTING GBM TUMORS AND TRACKING GROWTH WITHIN BBMS   
Initial experiments sought to characterize growth rates of two different types of brain 
cancer in both the small and large BBM systems. The tumor cell lines, U87 and MDA-MB-231- 
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BR (231-BR), were selected due to their sensitivity to TRAIL.136,188 To first investigate GBM, the 
human glioma line U87 was engineered to express the optical reporter mCh, and tumor cells were 
injected 2 mm deep into mini-BBMs at the same cell density used in traditional animal models: 
5´105 cells in 3 mL (Fig. 4.3A).104,189 Thirty minutes after implantation, BBMs were immersed in 
3D cell culture medium and moved to an incubator for long-term culture. A similar method was 
used in the life-size BBM model, where 3.0´107 mCh cells were implanted ~40 mm deep into the 
hydrogel, which was then transferred to the bioreactor (Fig. 4.3B). Tumor volume changes were 
then serially tracked using IVIS imaging. We found that 1 week after implantation, U87 tumor 
volumes increased 48-fold in the life-size BBM and greater than 52-fold in the mini-BBM (Fig. 
4.3C). These growth rates are comparable to experimentally determine in vivo growth rates when 
these tumors are established in nude mice.68 Thus, remaining experiments were all conducted using 
the same tumor cell density as described here.  
The testing was then expanded to explore metastatic brain cancer, specifically breast-to-
brain metastases. Human 231- BR cells, a brain-seeking variant of the common metastatic breast 
cancer line MDA-MB-231, was tested because it preferentially metastasizes to brain tissue.190 In 
the clinic, brain metastases often present as a multifocal disease. To model this growth pattern, 
multiple 231-BR tumor foci were established through implants of 2.5 and 5.0´105 cells 
contralateral to each other in both mini- and life-size BBMs (Fig. 4.3D, E). One week following 
implantation, serial kinetic imaging showed that tumor volume increased ap- proximately fourfold 
in both the mini- and life-size BBMs after 1 week (Fig. 4.3F), which also closely mimics the 
growth pattern that has previously been reported in nude mice.191 Altogether, these data provide 
evidence that tumor growth in BBMs closely mimic in vivo tumor growth kinetics, an important 




Figure 4.3. Brain Tumor Growth in BBMs. Representative images of GBM fluorescence over 
1 week of (A) small and (B) large BBMs. (C) Summary of tumor volumes fold day 0; n=2 for 
BBM and n=6 for mini-BBM. Additionally, representative images of metastatic breast cancer 
fluorescence over 1 week in (D) small and (E) large BBMs. (F) Summary data of tumor volumes 
fold day 0; n=2 for BBM and n=6 for mini-BBM. GBM, glioblastoma. 
 
4.2.4. NSC HOMING TO ESTABLISHED TUMOR IN BBM  
The ability of NSCs to migrate through the brain and actively seek out solid and invasive 
tumor foci is one of the most beneficial aspects of NSC-based therapy for brain cancer. The tumor-
homing capacity of NSCs has been extensively studied in mouse models of brain cancer, yet little 
is known about NSC migration distance capabilities in a human patient. The impact of NSC 
distance from the tumor and the resulting efficacy is unknown beyond the scale of a mouse. To 
assess NSC migration in the BBMs, mini-BBMs were first implanted with U87-mCh to establish 
cancer foci (referred to as ‘‘tumor’’) or with unlabeled fibroblasts to model nontumor foci (referred 
to as ‘‘nontumor’’). Three days post-tumor implantation, NSCs engineered through transduction 
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with LVs to express GFP (NSC-GFP) were implanted ~2mm lateral to the tumor or fibroblast 
focus (Fig. 4.4A). On days 1 and 7 post-implantation, a mini-BBM was fixed, and biopsies 
containing both cell types were collected and sectioned into ~1 mm slices using a rat brain slicer 
matrix. Fluorescent micrographs of the slices were captured using a stereomicroscope and 
fluorescent signal was quantified in ImageJ. Analysis showed that NSCs mi- grated more than 
100-fold further in the presence of tumor- containing BBM compared with nontumor-containing 
BBM, traversing 1.3-0.05 mm of the 2 mm gap between the sites of NSC and GBM implant over 
the 7-day period (Fig. 4.4B). Quantification of GFP signal in different regions near the injection 
site or GBM focus further confirmed this migration, as analysis of the fluorescent intensity showed 
78%-2.0% of NSC’s migrating region of the BBM when implanted near glioma cells for 1 week. 
When co- cultured with fibroblasts instead, NSCs exhibited no directional migration, with only 
25%-0.9% of GFP signal found in the migrating region in the nontumor BBM ImageJ (Fig. 4.4B).  
In the clinic, metastatic brain cancer often presents as multifocal disease. To investigate 
NSC migration to multi- focal tumors, we next implanted mCh-labeled 231-BR cells on 
contralateral hemispheres of the mini-BBMs ~5 mm apart. Three days later, NSCs were implanted 
~1 mm medially to the right tumor (RT), as shown in Figure 4C. After 1 week of coculture, mini-
BBMs were processed and fluorescent micrographs were captured and analyzed in ImageJ as 
before. Analysis showed that NSCs migrated 61-fold further in the presence of tumor compared 
with nontumor BBM, traversing 2.2-0.1 mm of the 4 mm gap between the NSC injection site and 
left tumor (LT) implant site over the 7-day period (Fig. 4.4D). Quantification of NSCs at the 
injection site or near the tumor foci further confirmed this migration, as analysis of the GFP 
intensity showed that 54%-1.8% of NSCs homed directionally toward the LT, which was, 
interestingly, further from the initial injection site compared with the RT. Around 29.2%-2.4% of  
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Figure 4.4. NSC Tumor Homing in BBMs. (A) Representative image of mini-BBM 
fluorescence measured in IVIS and stereo micrographs of fixed samples at days 1 and 7 after 
initiation of GBM and NSC coculture. (B) Summary data indicating maximum distance of NSC 
tumor homing and percentage of NSCs found in the migrating region to the left of the injection 
site as determined by GFP signal quantified in ImageJ. (+) Denotes coculture with tumor and (-) 
denotes coculture with no tumor. (C) Representative image of mini-BBM fluorescence measured 
in IVIS and stereomicrographs of fixed samples at days 1 and 7 after initiation of metastatic 
breast cancer and NSC coculture. (D) Summary data indicating maximum distance of NSC 
tumor homing and percentage of NSCs found in the migrating regions to the left and right of the 
injection site as determined by GFP signal quantified in ImageJ. (+) Denotes coculture with 
tumor and (-) or (no tumor) denotes coculture with no tumor. For all panels n = 3 fields from 
each two samples per time point, *p < 0.05; ***p < 0.001, ****p < 0.0001. GFP, green 
fluorescent protein; IVIS, in vivo imaging system; NSC, neural stem cell. 
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NSCs homed directionally toward the RT. Both enabled significantly more NSC migration than 
nontumor BBMs, where only 20%-2.0% of GFP signal could be found outside the injection site 
region (Fig. 4.4D). These results validate the tumor-homing property of NSCs and the usefulness 
of mini-BBMs for interrogating this key aspect of NSC therapy.  
4.2.5. INVESTIGATING THE IMPACT OF DISTANCE ON NSC-INDUCED TUMOR 
KILL  
In human patients, brain cancer foci are likely to present at varying distances from the site 
of NSC implant or infusion. However, the impact of tumor distance on NSC therapy is not easily 
investigated in vivo as the small size of the murine model makes implanting multiple tumor foci 
challenging and limits the distances that can be investigated. To use the BBM system to explore 
the impact of tumor distance on NSC therapy, U87-mCh were implanted in the mini- BBMs and 
NSCs engineered to express the antitumor agent TRAIL or control GFP were implanted at 0, 2.0, 
5.0, or 10 mm laterally from the tumor (Fig. 4.5A, B). Tumor progression was tracked with weekly 
kinetic imaging of U87- mCh fluorescence for 1 month. As shown in the summary graph (Fig. 
4.5C), NSCs delivered directly into the U87 tumor foci rapidly attenuated tumor progression, 
reducing tumor volumes to sub-detection levels by day 10 posttreatment and sustaining 
suppression through 28 days. NSCs implanted 2 mm from the tumor also significantly attenuate 
tumor growth by day 14, with decrease to sub-detection levels achieved by day 21. Attenuation of 
tumor growth from NSCs implanted 5 and 10 mm was also found to begin at day 14, however, 
reduction to sub-detection levels was not achieved until day 28 posttreatment (Fig. 4.5C). On day 
14, no statistical significance was observed when comparing the sham group to the 2-, 5-, and 10-
mm groups. Statistical significance was observed on day 21; compared with the sham control, the 
p-values for the 2-, 5-, and 10-mm groups were calculated to be 0.00084, 0.001809, and 0.004413, 
respectively. On day 28, the p-values for the 2-, 5-, and 10- mm groups were calculated to be 
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Figure 4.5. Efficacy of NSC-TRAIL as a Treatment Modality Determined Using Different 
Disease Models in Small BBMs. (A) Schematic of glioma and NSC-TRAIL implant method. 
(B) Representative images of fluorescent signal in BBMs at day 0 post-seeding. Green represents 
NSC-TRAIL and red represents U87-mCh. (C) Summary data of tumor volume fold change as 
determined by serial fluorescent imaging. (D) Schematic of breast cancer brain metastasis and 
NSC-TRAIL establishment; n³3. (E) Summary data of tumor volume fold change as determined 
by serial fluorescent imaging. In all experiments, ‘‘sham’’ is used to represent treatment with 
NSC-GFP instead of NSC-TRAIL; n=3. (F) Representative image of fluorescent signal in BBMs 
at day 0 post-seeding. Green represents NSC-TRAIL and red represents 231-BR-mCh. mCh, 
mCherry; TRAIL, TNFa-related apoptosis-inducing ligand. 
 
Lastly, we explored the potential efficacy of NSC therapy for multiple tumor foci. NSC 
migration is dependent on chemotaxis, thus it is possible that multifocal tumors may split the dose 
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of therapeutic NSCs across multiple foci, resulting in altered killing. To investigate this 
relationship, 231-BR-mCh cells were implanted in each hemisphere of the mini-BBM, ~5 mm 
apart. NSC-TRAIL or NSC-GFP were implanted directly adjacent to the tumor in the right hemi- 
sphere (RT), and tumor volumes were measured serially for 3 weeks (Fig. 4.5E). As shown in the 
summary data, serial kinetic imaging showed that NSC-TRAIL treatment reduced both tumor foci 
by greater than 70% 14 days posttreatment despite the closer proximity to the GBM in the right 
hemisphere (Fig. 4.5E). Interestingly, imaging results showed the tumor in the left hemisphere 
(LT) began to trend toward regrowth at day 21, and the change in signal was statistically significant 
compared with the GBM in the right hemisphere (Fig. 4.5E). In contrast, tumors in both 
hemispheres expanded rapidly in BBMs implanted with control NSC-GFP.  
4.2.6. BBM FABRICATION AND BIOREACTOR DESIGN  
Transmittance was calculated using light absorbance values of the mini-BBMs. Percent 
transmittance was determined to be 11.96 – 4.43 and 23.17 – 3.71 in mini-BBMs with and without 
PLA fibers, respectively (Fig. 4.2G).  
4.3. DISCUSSION 
Engineered NSC therapy is a promising new approach to cancer therapy. Multiple aspects 
of NSC migration and killing are impacted by the microenvironment, making the ideal potency 
assay for NSC-based therapeutics for brain cancer models that recapitulate the physical properties 
of brain tissue. With this in mind, BBMs were made to physically resemble the brain perivascular 
niche through embedding of microfiber PLA.192–196 PLA was chosen due to its biocompatibility as 
it has been used in several cell migration assays and tissue regeneration studies.102,196 Agarose as 
a base also presents a number of advantages. First, low concentration agarose gels (0.2–0.6%) have 
been shown to mimic the poroelasticity and backflow of the brain.197,198 Second, its deformability 
makes it easily injectable, and collective cell migration, which is more relevant to cell behavior in 
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vivo, can be studied.199,200 Third, it is considerably less expensive than other hydrogels designed 
to mimic the tissue microenvironment, such as collagen181,184,201 or Matrigel.180,202 Fourth, the 
Young’s modulus of soft agarose closely mimics that of healthy brain tissue; this is critical, 
because several studies have reported that the viscoelastic properties of a substrate can impact 
cells’ proliferation, differentiation, and migration characteristics.126,203–205 While agarose shows 
promise in this study, future optimization of BBMs will include exploration of other transparent 
matrices, such as alginate. Lastly, the transparent nature of the BBM allows for accessible serial 
imaging using in vivo fluorescent imaging systems (IVIS). IVIS imaging is efficient at locating 
the general presence of cells in a 2D space. To better understand the 3D spacing of cells, we 
performed initial experiments that explored the use of light-sheet microscopy (LSM) and confocal 
microscopy. For LSM, the BBM samples were prepared using the iDISCO+ protocol and stained 
with validated antibodies.206 However, NSCs were not visualized; this was likely caused by the 
inability of the antibodies to diffuse through the dense BBM. Confocal imaging was also nonideal 
due to the size of the sample and the spread of the cells in the x-y plane. Future studies combining 
BBMs with different imaging modalities would further optimize the BBM system and also provide 
unique insights into cellular and molecular events that occur during both the progression of brain 
cancers and following response to therapies.  
As a result, rationally designed BBMs were able to model both tumor growth and NSC 
tumor homing that occurs in vivo in nude mouse xenograft models of brain cancer.68,191,207 From 
there, experiments using BBMs revealed the impact of distance between NSC and tumor foci on 
therapeutic efficacy. Clinically, GBM tumor regrowth occurs within 2 cm of the tumor resection 
cavity.208 Therefore, the distances of 2, 5, and 10mm were selected to mimic these clinical findings. 
When implanting therapeutic NSCs and GBM, onset and extent of tumor suppression varied 
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inversely with initial NSC distance from the established tumor focus. While therapeutic NSCs 
implanted into 231- BR models did not impact the timing of the onset of tumor suppression, the 
tumor contralateral to the NSC initial injection site began to recur <2 weeks later. More 
investigation into the mechanism for recurrence is needed, but it could be due to metastatic 
invasion and therefore escape from the region of effect created by diffusion of TRAIL secreted by 
therapeutic NSCs.174,181,197,209,210 Additionally, while SDF-1, CXCR4, VEGF, and EGF are 
believed to play roles in NSC migration, the exact mechanism has yet to be elucidated.186 To 
maximize efficacy of NSC-based therapies, optimization of dosing strategies is needed; more 
research into the effects of cell density, total cell dose, frequency of dosing, and potential for cell 
conditioning, among others, on cell migration, and therefore potency, must be conducted.  
In the case of autologous NSC-based therapies, a method for high-throughput screening of 
migration kinetics between cells derived from different patients is needed to determine reduction 
to practice. We present this multiscale 3D biomimetic model of brain cancer to fulfill this need. It 
is our hope that ongoing studies of efficacy using NSC-based therapies against GBM in life-size 
BBMs can accurately reflect what can be expected as this therapeutic approach is adapted for 
clinical use. Using this method to examine the effect of dosing strategy on therapeutic cells at a 
human-size scale should provide more reliable data than current commonly used approaches, as 
cells prefer to migrate through a soft matrix rather than through a membrane or across a rigid 
surface.182  
4.4. MATERIALS & METHODS 
4.4.1. CELL LINES 
U87 glioma cells were purchased from the American Type Culture Collection and cultured 
according to manufacturer’s specifications. Human fibroblasts (NHF1) were provided by W. 
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Kauffman (University of North Carolina School of Medicine). 231-BR cells were provided by 
Carey Anders (University of North Carolina Lineberger Cancer Center). C17 mouse NSCs were 
used in all NSC experiments and were acquired from Sigma-Aldrich. Each cell line was cultured 
at 37°C, 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM, 10% fetal bovine serum 
[FBS], 1% penicillin– streptomycin; Gibco). Cells were engineered to express green fluorescent 
protein (GFP), mCherry (mCh) fluorescent protein, and/or TNFa-related apoptosis-inducing 
ligand (TRAIL) through a 24-h transduction with lentivirus (LV) in the presence of polybrene (8 
mg/mL; Sigma). All LV constructs were packaged as LV vectors in 293T cells using a helper 
virus-free packaging system as described previously.68,69  
4.4.2. BBM FABRICATION 
The BBMs were fabricated by mixing 3D cell culture medium (DMEM [1% antibiotic–
antimycotic, 1% gluta- mine, 2% FBS, no phenol red]; Gibco) with a 1.2% w/v agarose (Gene 
Mate LE Agarose; BioExpress) dissolved in phosphate-buffered saline (PBS) at a 1:1 ratio. This 
solution was poured into a plastic mold with 2.2 mg/mL meltblown PLA 6100 scaffold 
microfibers, which were obtained from the Non-Wovens Institute at North Carolina State 
University. Before being added to the mold, the PLA fibers were sterilized using ultraviolet (UV) 
light and hydrated in the 3D medium overnight. Next, the fibers were manipulated using forceps 
to distribute the fibers homogenously throughout the BBM solution as it cooled. The BBMs were 
incubated at room temperature to allow gelation before transferring from the mold to the 
appropriate cell culture incubator. BBMs were kept hydrated using 3D medium and incubated at 
37°C/5% CO2. Medium was changed every 3–4 days.  
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4.4.3. BBM CELL SEEDING  
To inoculate the BBM with NSCs and tumor cells, the cells were suspended at the desired 
concentration in DMEM. To allow for injection without backflow, the pipette was inserted 10 mm 
into the BBM, then withdrawn ~5 mm to create a cavity in which to inject the cells. Cells were 
injected at a concentration of 5.0´104 cells in 3 mL for the mini-BBMs or 3.0´107 in 100 mL for 
the life-size BBMs. The seeded BBM was incubated at room temperature for 30 min to allow the 
cells to adhere before being immersed in 3D media and incubated at 37°C, 5% CO2.  
4.4.4. SCANNING ELECTRON MICROSCOPY 
BBM samples were prepared, seeded, and cultured as described above. Fourteen days post-
seeding, BBMs were fixed using 10% formalin then transferred to 1 · PBS. Using an 8 mm biopsy 
punch and scalpel, samples were trimmed to the region surrounding the injection site, where cells 
would be most likely to persist. The samples were then dehydrated sequentially in 50%, 75%, 90%, 
and 100% ethanol. Next, samples were dried using a critical point dryer (Tousimis Autosamdi-
931), mounted on aluminum stubs, and sputter coated with 8nm of gold–palladium (Cressington 
Sputter Coater 108auto). The samples were imaged on a FEI Helios 600 Nanolab Dual Beam 
System microscope using a 2 kV accelerating voltage.  
4.4.5. BBM SERIAL IMAGING  
The BBMs were imaged on an in vivo imaging system (IVIS Kinetic; Caliper LifeSciences) 
for fluorescence. Media were aspirated from the samples before imaging. Cells expressing GFP 
were probed for using an excitation and emission wavelength spectrum of 465–500 nm, and the 
mCh-expressing cells were observed using a spectrum of 570–620 nm. An exposure time of 5 s 
was used for all im- aging sessions. Tumor signal was quantified using Living Image software. 
Following imaging, the BBMs were resuspended in 3D media and returned to the incubator.  
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4.4.6. EVALUATING BBM OPTICAL TRANSPARENCY  
Mini-BBMs were fabricated as previously described and kept in a six-well plate with 3D 
media. Absorbance was read at 426 nm using a Molecular Devices SpectraMax M2 plate reader. 
Percent transmittance was calculated using the following formula, %( = 10(#$%), where A is 
absorbance and T is transmittance. Data were analyzed using Student’s t-test with Welch’s 
correction.  
4.4.7. STATISTICS 
Data were analyzed by the Student’s t-test, one-way analysis of variance/Bonferroni, or 
log-rank test when ap- propriate. Data were expressed as mean ± standard deviation. Significance 
between groups was denoted by *p < 0.05; **p < 0.01; ***p < 0.001. Replicate number is defined 
by n in figures.   
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CHAPTER 5: NEXT GENERATION CELL DELIVERY SYSTEMS 
5.1. FUTURE DIRECTIONS AND CONSIDERATIONS 
Though considerable progress has been made towards the development of scaffolds for the 
delivery of iNSCs, the optimal system has yet to be found. As discussed in Chapter 1, TISSEEL®, 
Gelfoam®, HySTEM™, Ace-DEX, and PLA demonstrated how scaffolds could improve stem cell 
persistence and survival outcomes. Despite the benefits observed with FLOSEAL® outline in 
Chapter 2, significant and consistent improvements in survival outcomes were not observed. In 
order to achieve these goals, the next generation of cell delivery systems need to address the pitfalls 
of previous formulations through rational design. 
Cell binding, material biocompatibility, handleability, degradation, and size are key 
considerations when designing scaffold systems. However, these properties can only be tuned to a 
certain degree, if at all, when using an off-the-shelf product like TISSEEL® or FLOSEAL®. The 
level of tunability necessary to produce the optimal scaffold requires more sophisticated 
fabrication methods and materials. To develop the next generation of cell delivery materials, 
continuous liquid interface production (CLIP) and peptide nanofibers are two of the most 
promising technologies. 
5.1.  CONTINUOUS LIQUID INTERFACE PRODUCTION 
CLIP is a new additive manufacturing technology, with the first patent filed in 2014 and 
data published in 2015.211,212 In brief, CLIP uses a bottom-up printing strategy wherein a pool of 
liquid resin sits above an oxygen-permeable window, and below the window sits a ultraviolet light 
source. With this set-up, a “dead zone” is created, which allows for a thin region of uncured resin 
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and oxygen flow. The invention of CLIP drastically decreased the time taken to print an object by 
controlling oxygen in the resin pool. Additionally, CLIP has the added ability to produce objects 
with a feature resolution of less than 100 µm, a  vast improvement over traditional 3D printers.211,213 
Since its inception, CLIP has since demonstrated its versatility in creating a host of products, 
including dentures, medical swabs, and surgical tools that are already in commercial 
production.211,214  
More recently, researchers have begun to explore how CLIP can be used with a variety of 
synthetic polymers to create implantable medical devices. Polycaprolactone and poly(ethylene 
glycol), nano-hydroxyapatite and poly(ethylene glycol)diacrylate, and methacrylated 
poly(dodecamethylene citrate) have been studied for their use in small molecule drug delivery, 
tissue engineered bone constructs, and bioresorbable cardiovascular stents, respectively.213,215–217 
Given the preliminary success of these devices, there is evidence to support the testing of CLIP 
for iNSC delivery scaffolds. 
5.2. PEPTIDE NANOFIBERS 
While CLIP offers a new way to produce intricate scaffold architectures, peptide scaffolds 
are an innovative materials-based strategy, and their flexibility makes them an attractive choice. 
As discussed in Chapter 2, the mechanical properties and interactions between a cell and material 
can impact gene expression. With peptide scaffolds, the mechanical properties can be easily tuned 
by controlling the salt concentration of the gelling solution.218 Additionally, the abundance of 
functional groups allows for conjugation of a variety of cells, growth factors, and other 
therapeutics.218–220 In the case of iNSC therapy, peptide scaffolds would allow for combination 
therapies, i.e. cells and an additional therapy, to be delivered simultaneously, potentially resulting 
in a new, synergistic treatment. The scaffolds could also be engineered with growth factors or 
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proteins to support iNSC growth. Lastly, peptide scaffolds also offer the benefit of being injectable 
and bioresorbable.218,220 Overall, peptide scaffolds offer a promising solution to the drawbacks of 




CHAPTER 6: SUMMARY AND PROSPECTUS 
 Biomaterial matrices for the delivery of therapeutic iNSCs have proven vital to their 
persistence and therapeutic longevity. The data presented in this dissertation: (a) demonstrates 
the profound impact FLOSEAL® has on iNSC persistence in vivo, (b) establishes the safety of 
iNSCs delivered with and without FLOSEAL® in a large animal model, (c) presents novel GBM 
models to screen and validate cell therapies, and (d) looks into the next generation of cell 
delivery systems.  
 Chapter 2 discussed the importance of delivery matrices, specifically the gelatin-
thrombin mixture, FLOSEAL®. Through rigorous investigation, FLOSEAL® proved to be a 
desirable material that supported iNSC proliferation and persistence in murine models. Although 
persistence did not correlate to increased survival outcomes in all treated animals, these studies 
highlighted the need for delivery matrices that could provide an initial burst release of 
therapeutics followed by a sustained release. Furthermore, the gene expression profiles of iNSCs 
cultured in FLOSEAL® in vitro produced interesting results. In line with previous studies, 
differentiation, proliferation, pluripotency, and some NSC markers were downregulated. qRT-
PCR also provided insight on potential iNSC migration markers. Overall, FLOSEAL® remains a 
promising candidate for iNSC delivery. 
 In the following chapter, the first safety and toxicity study of autologous iNSCs was 
presented. This chapter assessed the process and challenges of large-scale cell manufacturing as 
well as the delivery of iNSCs using a clinically-relevant ICV infusion device and FLOSEAL®. 
Through serial blood, urine, and CSF analysis, MRI, and post-mortem histology, iNSCs were 
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found to exhibit limited toxicity in canines. The positive outcomes from this study will 
ultimately inform future efficacy studies in large animal models.  
 Chapter 4 introduced an innovative 3D culture system to screen and optimize stem cell 
therapy. The BBMs were able to support the growth of implanted tumors and therapeutic stem 
cells, and importantly, the BBMs allowed for serial optical imaging. Not only did the culture 
system prove practical, but it also provides an alternative to animal research. BBMs are cheaper, 
more high-throughput, and can be cultured in an easily 3D-printed bioreactor. The development 
of culture systems like BBMs will help expedite cell therapy research. 
 Lastly, Chapter 5 discussed cell delivery systems that are under development. The CLIP 
and peptide scaffolds seek to address the pitfalls of previous researched scaffolds through 
rational design and enhanced tunability. Although both scaffolds are in the preliminary stages of 
development, they have shown promise in promoting stem cell seeding efficiency, persistence, 
and migration. However, continued research and optimization will be necessary to select a 
formulation that promotes cell persistence and migration while simultaneously providing optimal 
therapeutic profiles. 
Taken together, this data presented in this dissertation provides the foundation for future 
cell delivery matrix optimization. As research and technology continue to advance, 
improvements in bioreactors, material formulations, and tumor models will be vital to push 
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